Zoetis (ZTS) 10-Q 13 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 29, 2013	Nov. 08, 2013
Document Document and Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	29-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'ZTS	'
Entity Registrant Name	'Zoetis Inc.	'
Entity Central Index Key	'0001555280	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	500,006,833

CONDENSED_CONSOLIDATED_AND_COM

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF INCOME(UNAUDITED) (USD $)	3 Months Ended				9 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Sep. 29, 2013		Sep. 30, 2012		Sep. 29, 2013		Sep. 30, 2012
Income Statement [Abstract]	'		'		'		'
Revenue	$1,103	[1]	$1,019	[1]	$3,307	[1]	$3,160	[1]
Costs and expenses:	'		'		'		'
Cost of sales(a)	385	[2]	359	[2]	1,203	[2]	1,130	[2]
Selling, general and administrative expenses(a)	399	[2]	335	[2]	1,155	[2]	1,017	[2]
Research and development expenses(a)	93	[2]	94	[2]	278	[2]	288	[2]
Amortization of intangible assets(a)	15	[2]	16	[2]	45	[2]	48	[2]
Restructuring charges and certain acquisition-related costs	3		6		-10		55
Interest expense, net of capitalized interest	29		7		83		23
Other (income)/deductions—net	-6		-11		-11		-37
Income before provision for taxes on income	185	[3]	213	[3]	564	[3]	636	[3]
Provision for taxes on income	54		52		165		190
Net income before allocation to noncontrolling interests	131		161		399		446
Less: Net income/(loss) attributable to noncontrolling interests	0		-1		0		0
Net income attributable to Zoetis Inc.	$131		$162		$399		$446
Earnings per share attributable to Zoetis Inc. stockholders:	'		'		'		'
Basic (in dollars per share)	$0.26		$0.32		$0.80		$0.89
Diluted (in dollars per share)	$0.26		$0.32		$0.80		$0.89
Weighted-average common shares outstanding:	'		'		'		'
Basic (in shares)	500,000		500,000		500,000		500,000
Diluted (in shares)	500,354		500,000		500,227		500,000
Dividends paid per common share (in dollars per share)	$0.07		$0		$0.20		$0
[1]	Revenue denominated in euros were $159 million and $493 million in the three and nine months ended September 29, 2013, respectively and $142 million and $464 million in the three and nine months ended September 30, 2012, respectively.
[2]	Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to finite-lived acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, general and administrative expenses or Research and development expenses, as appropriate, in the condensed consolidated and combined statements of income.
[3]	Defined as income before provision for taxes on income.

CONDENSED_CONSOLIDATED_AND_COM1

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (USD $)	3 Months Ended				9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013		Sep. 30, 2012		Sep. 29, 2013		Sep. 30, 2012
Statement of Comprehensive Income [Abstract]	'		'		'		'
Net income before allocation to noncontrolling interests	$131		$161		$399		$446
Other comprehensive income/(loss), net of taxes and reclassification adjustments(a):	'		'		'		'
Foreign currency translation adjustments, net	-62	[1]	22	[1]	-79	[1]	-106	[1]
Benefit plans: Actuarial gains/(losses), net	0	[1]	2	[1]	-3	[1]	2	[1]
Total other comprehensive income/(loss), net of tax	-62		24		-82		-104
Comprehensive income before allocation to noncontrolling interests	69		185		317		342
Less: Comprehensive income/(loss) attributable to noncontrolling interests	0		-1		0		0
Comprehensive income attributable to Zoetis Inc.	$69		$186		$317		$342
[1]	Presented net of reclassification adjustments and tax impacts, which are not significant in any period presented. Reclassification adjustments related to benefit plans are generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, general and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated and combined statements of income.

CONDENSED_CONSOLIDATED_AND_COM2

CONDENSED CONSOLIDATED AND COMBINED BALANCE SHEETS (UNAUDITED) (USD $)	Sep. 29, 2013		Dec. 31, 2012
In Millions, unless otherwise specified
Assets	'		'
Cash and cash equivalents	$389	[1]	$317	[1]
Accounts receivable, less allowance for doubtful accounts of $36 in 2013 and $49 in 2012	1,110	[1]	900	[1]
Inventories	1,290	[1]	1,345	[1]
Current deferred tax assets	66	[1]	101	[1]
Other current assets	228	[1]	201	[1]
Total current assets	3,083	[1]	2,864	[1]
Property, plant and equipment, less accumulated depreciation of $996 in 2013 and $1,011 in 2012	1,252	[1]	1,241	[1]
Goodwill	980	[1]	985	[1]
Identifiable intangible assets, less accumulated amortization	815	[1]	868	[1]
Noncurrent deferred tax assets	70	[1]	216	[1]
Other noncurrent assets	59	[1]	88	[1]
Total assets	6,259	[1]	6,262	[1]
Liabilities and Equity	'		'
Short-term borrowings, including current portion of allocated long-term debt in 2012	10	[1]	73	[1]
Accounts payable	482	[1]	319	[1]
Accrued compensation and related items	184	[1]	194	[1]
Income taxes payable	121	[1]	30	[1]
Dividends payable	33	[1]	0	[1]
Other current liabilities	478	[1]	507	[1]
Total current liabilities	1,308	[1]	1,123	[1]
Long-term debt	3,642	[1]	0	[1]
Allocated long-term debt	0	[1]	509	[1]
Noncurrent deferred tax liabilities	269	[1]	323	[1]
Other taxes payable	41	[1]	159	[1]
Other noncurrent liabilities	133	[1]	107	[1]
Total liabilities	5,393	[1]	2,221	[1]
Commitments and contingencies	'	[1]	'	[1]
Business unit equity	0	[1]	4,183	[1]
Common stock, $0.01 par value: 5,000 authorized, 500 issued and outstanding	5	[1]	0	[1]
Additional paid-in capital	876	[1]	0	[1]
Retained earnings	207	[1]	0	[1]
Accumulated other comprehensive loss	-245	[1]	-157	[1]
Total Zoetis Inc. equity	843	[1]	4,026	[1]
Equity attributable to noncontrolling interests	23	[1]	15	[1]
Total equity	866	[1]	4,041	[1]
Total liabilities and equity	$6,259	[1]	$6,262	[1]
[1]	The condensed consolidated balance sheet as of September 29, 2013 has been prepared under a different basis of presentation than the condensed combined balance sheet as of December 31, 2012, which significantly impacts comparability. See Note 3. Basis of Presentation.

CONDENSED_CONSOLIDATED_AND_COM3

CONDENSED CONSOLIDATED AND COMBINED BALANCE SHEETS (UNAUDITED) (PARENTHETICAL) (USD $)	Sep. 29, 2013	Dec. 31, 2012
In Millions, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Allowance for doubtful accounts	$36	$49
Accumulated depreciation	$996	$1,011
Common stock, par value (in dollars per share)	$0.01	'
Common stock, shares authorized	5,000,000,000	'
Common stock, shares issued	500,006,833	'
Common stock, shares outstanding	500,006,833	'

CONDENSED_CONSOLIDATED_AND_COM4

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF EQUITY(UNAUDITED) CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF EQUITY(UNAUDITED) (USD $)		Total		Business Unit Equity		Common Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comp. Income/(Loss)	Equity Attributable to Noncontrolling Interests
In Millions, unless otherwise specified
Beginning balance at Dec. 31, 2011		$3,736		$3,785	[1]	'		'	$0	($65)	$16
Increase (Decrease) in Stockholders' Equity [Roll Forward]		'		'		'		'	'	'	'
Comprehensive income/(loss)		342		446	[1]	'		'	'	-104	'
Share-based compensation expense		18		18	[1]	'		'	0	'	'
Dividends declared and paid		-63		-63	[1]	'		'	'	'	'
Net transfers between Pfizer and noncontrolling interests		0		1	[1]	'		'	'	'	-1
Net transfers - Pfizer		76		76	[1]	'		'	'	'	'
Ending balance at Sep. 30, 2012		4,109		4,263	[1]	'		'	0	-169	15
Beginning balance at Dec. 31, 2012		4,041	[2]	4,183	[1]	'		0	0	-157	15
Increase (Decrease) in Stockholders' Equity [Roll Forward]		'		'		'		'	'	'	'
Comprehensive income/(loss)		317		94	[1]	'		0	305	-82	0
Share-based compensation expense		37		3	[1]	'		34	'	'	'
Dividends declared and paid		-98		'		'		'	-98	'	'
Net transfers - Pfizer		-271		-271	[1]	'		0	0	0	0
Separation adjustments(c)	[3]	450		414	[1]	'		34	'	-6	8
Employee benefit plan contribution from Pfizer Inc.(d)	[4]	1		0	[1]	'		1	0	0	0
Reclassification of net liability due to Pfizer Inc.(e)	[5]	-60		-60	[1]	'		'	'	'	'
Consideration paid to Pfizer Inc. in connection with the Separation(f)	[6]	-3,551		'		'		-3,551	'	'	'
Issuance of common stock to Pfizer Inc. in connection with the Separation and relassification of Business Unit Equity(f)	[6]	0		-4,363	[1]	5	[7]	4,358	'	'	'
Ending balance at Sep. 29, 2013		$866	[2]	'		$5	[7]	$876	$207	($245)	$23
[1]	All amounts associated with Business Unit Equity relate to periods prior to the Separation. See Note 2A. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: The Separation.
[2]	The condensed consolidated balance sheet as of September 29, 2013 has been prepared under a different basis of presentation than the condensed combined balance sheet as of December 31, 2012, which significantly impacts comparability. See Note 3. Basis of Presentation.
[3]	For additional information, see Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.
[4]	Represents contributed capital from Pfizer Inc. associated with service credit continuation for certain Zoetis Inc. employees in Pfizer Inc.'s U.S. qualified defined benefit and U.S. retiree medical plans. See Note 12. Benefit Plans.
[5]	Represents the reclassification of the Receivable from Pfizer Inc. and the Payable to Pfizer Inc. from Business Unit Equity as of the Separation date. See Note 2A. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: The Separation.
[6]	Reflects the Separation transaction. See Note 2A. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: The Separation.
[7]	As of SeptemberB 29, 2013, there were 500,006,833 outstanding shares of common stock.

CONDENSED_CONSOLIDATED_AND_COM5

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF EQUITY(UNAUDITED) (PARENTHETICAL)	Sep. 29, 2013
Statement of Stockholders' Equity [Abstract]	'
Common Stock, Shares, Outstanding	500,006,833

CONDENSED_CONSOLIDATED_AND_COM6

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013		Sep. 30, 2012
Operating Activities	'		'
Net income before allocation to noncontrolling interests	$399		$446
Adjustments to reconcile net income before noncontrolling interests to net cash provided by/(used in) operating activities	'		'
Depreciation and amortization expense	151	[1]	156	[1]
Share-based compensation expense	37		18
Asset write-offs and asset impairments	4		9
Deferred taxes	-47		-81
Employee benefit plan contribution from Pfizer Inc.	1		'
Other non-cash adjustments	0		-2
Other changes in assets and liabilities, net of acquisitions and divestitures and transfers with Pfizer Inc.	-162		-402
Net cash provided by operating activities	383		144
Investing Activities	'		'
Purchases of property, plant and equipment	-135		-81
Net proceeds from sales of assets	7		0
Other investing activities	0		-8
Net cash used in investing activities	-128		-89
Financing Activities	'		'
Increase in short-term borrowings, net	11		0
Proceeds from issuance of long-term debtbsenior notes, net of discount and fees	2,625		0
Consideration paid to Pfizer Inc. in connection with the Separation(a)	-2,559	[2]	0	[2]
Cash dividends paid(b)	-65	[3]	-63	[3]
Other net financing activities with Pfizer Inc.	-184		63
Net cash (used in)/provided by financing activities	-172		0
Effect of exchange-rate changes on cash and cash equivalents	-11		-1
Net increase in cash and cash equivalents	72		54
Cash and cash equivalents at beginning of period	317	[4]	79
Cash and cash equivalents at end of period	389	[4]	133
Cash paid during the period for:	'		'
Income taxes	77		276
Interest, net of capitalized interest	60		31
Non-cash transactions:	'		'
Dividends declared, not paid	33		0
Zoetis Inc. senior notes transferred to Pfizer Inc. in connection with the Separation(c)	$992	[5]	$0	[5]
[1]	Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
[2]	Reflects the Separation transaction. Amount is net of the non-cash portion. See Note 2A. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: The Separati
[3]	Payments to other non-Zoetis Pfizer Inc. entities for the
[4]	The condensed consolidated balance sheet as of September 29, 2013 has been prepared under a different basis of presentation than the condensed combined balance sheet as of December 31, 2012, which significantly impacts comparability. See Note 3. Basis of Presentation.
[5]	Reflects the non-cash portion of the Separation transaction. See Note 2A. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: The Separation.

Organization

Organization	9 Months Ended
	Sep. 29, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization	'
	Organization
	Zoetis Inc. (collectively, Zoetis, the company, we, us or our) is a global leader in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. We organize and operate our business in four geographic regions: the United States (U.S.); Europe/Africa/Middle East (EuAfME); Canada/Latin America (CLAR); and Asia/Pacific (APAC).
	We market our products in more than 120 countries, including developed markets and emerging markets. Our revenue is mostly generated in the U.S. and EuAfME. We have a diversified business, marketing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals); and within five major product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Separation_Activities_and_Init

Separation Activities and Initial Public Offering	9 Months Ended
	Sep. 29, 2013
Separation Activities and Initial Public Offering [Abstract]	'
The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer	'
	The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer
	Pfizer Inc. (Pfizer) formed Zoetis to acquire, own and operate the animal health business of Pfizer. On June 24, 2013, Pfizer completed an exchange offer resulting in the full separation of Zoetis from Pfizer. For additional information, see E. Exchange Offer.
	A.	The Separation
	In the first quarter of 2013, through a series of steps (collectively, the Separation), Pfizer transferred to us its subsidiaries holding substantially all of the assets and liabilities of its animal health business. In exchange, we transferred to Pfizer: (i) all of the issued and outstanding shares of our Class A common stock; (ii) all of the issued and outstanding shares of our Class B common stock; (iii) $1.0 billion in senior notes (see C. Senior Notes Offering below); and (iv) an amount of cash equal to substantially all of the net proceeds received in the senior notes offering (approximately $2.5 billion).
	B.	Adjustments Associated with the Separation
	In connection with the Separation, certain animal health assets and liabilities included in the pre-Separation balance sheet were retained by Pfizer and certain non-animal health assets and liabilities (not included in the pre-Separation balance sheet) were transferred to Zoetis. The adjustments to the historical balance sheet of Zoetis (collectively, the Separation Adjustments) representing approximately $450 million of net liabilities retained by Pfizer, were primarily related to the following:
	•	The removal of inventories (approximately $74 million), property, plant and equipment (approximately $28 million) and miscellaneous other net liabilities (approximately $21 million) associated with certain non-dedicated manufacturing sites that were retained by Pfizer;
	•	The addition of property, plant and equipment (approximately $56 million) associated with a non-dedicated manufacturing site that was transferred to us by Pfizer (and then leased back to Pfizer under operating leases), and the removal of the inventory (approximately $46 million) and net other assets (approximately $4 million) at that site as these assets were retained by Pfizer;
	•	The addition of net benefit plan liabilities (approximately $25 million);
	•	The elimination of (i) noncurrent deferred tax assets (some of which were included within noncurrent deferred tax liabilities due to jurisdictional netting) related to net operating loss and tax credit carryforwards; (ii) net tax liabilities associated with uncertain tax positions; (iii) noncurrent deferred tax liabilities related to deferred income taxes on unremitted earnings; and (iv) other allocated net tax assets, all of which (approximately $49 million in net tax asset accounts) were retained by Pfizer;
	•	The addition of (i) noncurrent deferred tax assets (approximately $8 million, some of which were included within noncurrent deferred tax liabilities due to jurisdictional netting) related to net benefit plan liabilities transferred to us by Pfizer; (ii) noncurrent deferred tax assets (approximately $2 million) related to net operating loss and tax credit carryforwards; and (iii) noncurrent deferred tax liabilities (approximately $2 million) related to property, plant and equipment transferred to us by Pfizer;
	•	The elimination of allocated long-term debt (approximately $582 million), allocated accrued interest payable (approximately $16 million) and allocated unamortized deferred debt issuance costs (approximately $2 million) that were retained by Pfizer;
	•	Certain net financial assets retained by Pfizer (approximately $45 million);
	•	The removal of cash (approximately $7 million), inventories (approximately $5 million), property, plant and equipment (approximately $8 million), miscellaneous other assets (approximately $3 million) and other miscellaneous liabilities (approximately $2 million) associated with non-U.S. Pfizer businesses that did not transfer to us from Pfizer;
	•	The addition of net receivables from Pfizer (approximately $5 million) associated with certain foreign taxes directly resulting from certain aspects of the Separation that were the responsibility of Pfizer under the terms of the tax matters agreement, see Note 7B. Income Taxes: Tax Matters Agreement;
	•	The addition of (i) inventory (approximately $15 million); (ii) net deferred tax assets (approximately $1 million); and (iii) miscellaneous other assets (approximately $5 million) transferred to us by Pfizer, and the removal of (i) property, plant and equipment (approximately $2 million); (ii) miscellaneous other liabilities (approximately $57 million), and (iii) the elimination of prepaid taxes (approximately $4 million) that were retained by Pfizer; and
	•	The addition of net benefit plan liabilities (approximately $16 million) associated with certain international plans that will be transferred from Pfizer to Zoetis in 2014. See Note 12. Benefit Plans.
	The Separation Adjustment associated with Accumulated Other Comprehensive Income reflects the accumulated currency translation adjustment based on the actual legal entity structure of Zoetis.
	C.	Senior Notes Offering
	In connection with the Separation, on January 28, 2013, we issued $3.65 billion aggregate principal amount of our senior notes (the senior notes offering) in a private placement, with an original issue discount of $10 million. For additional information, see Note 9D. Financial Instruments: Senior Notes Offering.
	D.	Initial Public Offering (IPO)
	After the Separation, on February 6, 2013, an IPO of 99,015,000 shares of our Class A common stock (including the exercise of the underwriters' over-allotment option) at a price of $26.00 per share was completed. Pfizer retained the net proceeds from the IPO.
	Immediately following the IPO, there were 99,015,000 outstanding shares of Class A common stock and 400,985,000 outstanding shares of Class B common stock. The rights of the holders of Class A common stock and Class B common stock are identical, except with respect to voting and conversion rights. Following the IPO, Pfizer owned all of the outstanding shares of our Class B common stock, all of which was converted to Class A common stock in connection with the Exchange Offer. See E. Exchange Offer. There are no longer any shares of our Class B common stock outstanding.
	In connection with the IPO, we entered into certain agreements that provide a framework for an ongoing relationship with Pfizer. For additional information, see Note 17B. Transactions and Agreements with Pfizer: Agreements with Pfizer.
	E.	Exchange Offer
	On May 22, 2013, Pfizer announced an exchange offer (the Exchange Offer) whereby Pfizer shareholders could exchange a portion of Pfizer common stock for Zoetis common stock. The Exchange Offer was completed on June 24, 2013, resulting in the full separation of Zoetis and the disposal of Pfizer's entire ownership and voting interest in Zoetis.

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 29, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited condensed consolidated and combined financial statements were prepared following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three and nine-month periods ended August 25, 2013 and August 26, 2012.
	Revenue, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
	We are responsible for the unaudited condensed consolidated and combined financial statements included in this Form 10-Q. The condensed consolidated and combined financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results. The information included in this interim report should be read in conjunction with the combined financial statements and accompanying notes included in the Company’s 2012 Annual Report on Form 10-K.
	A.	Basis of Presentation Prior to the Separation
	Prior to the Separation, the combined financial statements were derived from the consolidated financial statements and accounting records of Pfizer and included allocations for direct costs and indirect costs attributable to the operations of the animal health business of Pfizer. The pre-Separation financial statements and activities do not purport to reflect what the results of operations, comprehensive income/(loss), financial position, equity or cash flows would have been had we operated as a standalone public company during the period presented.
	•	The condensed combined statements of income for the three and nine months ended September 30, 2012 and the pre-Separation period included in the condensed consolidated statement of income for the nine months ended September 29, 2013 include allocations from certain support functions (Enabling Functions) that are provided on a centralized basis within Pfizer, such as expenses for business technology, facilities, legal, finance, human resources, and, to a lesser extent, business development, public affairs and procurement, among others, as Pfizer does not routinely allocate these costs to any of its business units. These allocations are based on either a specific identification basis or, when specific identification is not practicable, proportional allocation methods (e.g., using third-party sales, headcount, etc.), depending on the nature of the services.
	Costs associated with business technology, facilities and human resources were allocated primarily using proportional allocation methods and, for legal and finance, primarily using specific identification. In all cases, for support function costs where proportional allocation methods were used, we determined whether the costs are primarily influenced by headcount (such as a significant majority of facilities and human resources costs) or by the size of the business (such as most business technology costs), and we also determined whether the associated scope of those services provided are global, regional or local. Based on those analyses, the costs were allocated based on our share of worldwide revenue, domestic revenue, international revenue, regional revenue, country revenue, worldwide headcount, country headcount or site headcount, as appropriate.
	As a result, costs associated with business technology and legal that were not specifically identified were mostly allocated based on revenue drivers and, to a lesser extent, based on headcount drivers; costs associated with finance that were not specifically identified were all allocated based on revenue drivers; and costs associated with facilities and human resources that were not specifically identified were predominantly allocated based on headcount drivers.
	•	The condensed combined statement of income for the three and nine months ended September 30, 2012 and the pre-Separation period included in the condensed consolidated statement of income for the nine months ended September 29, 2013 include allocations of certain manufacturing and supply costs incurred by manufacturing plants that are shared with other Pfizer business units, Pfizer’s global external supply group and Pfizer’s global logistics and support group (collectively, Pfizer Global Supply, or PGS). These costs may include manufacturing variances and changes in the standard costs of inventory, among others, as Pfizer does not routinely allocate these costs to any of its business units. These allocations are based on either a specific identification basis or, when specific identification is not practicable, proportional allocation methods, such as animal health identified manufacturing costs, depending on the nature of the costs.
	•	The condensed combined statement of income for the three and nine months ended September 30, 2012 and the pre-Separation period included in the condensed consolidated statement of income for the nine months ended September 29, 2013 also include allocations from the Enabling Functions and PGS for restructuring charges, integration costs, additional depreciation associated with asset restructuring and implementation costs, as Pfizer does not routinely allocate these costs to any of its business units. For additional information about allocations of restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives, see Note 5. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.
	•	The condensed combined statement of income for the three and nine months ended September 30, 2012 and the pre-Separation period included in the condensed consolidated statement of income for the nine months ended September 29, 2013 include an allocation of share-based compensation expense and certain other compensation expense items, such as certain fringe benefit expenses, maintained on a centralized basis within Pfizer, as Pfizer does not routinely allocate these costs to any of its business units. For additional information about allocations of share-based payments, see Note 13. Share-Based Payments.
	•	The condensed combined balance sheet as of December 31, 2012 reflects all of the assets and liabilities of Pfizer that are either specifically identifiable or are directly attributable to Zoetis and its operations. For benefit plans, the combined balance sheet only includes the assets and liabilities of benefit plans dedicated to animal health employees. For debt, see below.
	•	The condensed combined balance sheet as of December 31, 2012 includes an allocation of long-term debt from Pfizer that was issued to partially finance the acquisition of Wyeth (including Fort Dodge Animal Health (FDAH)). The debt and associated interest-related expenses, including the effect of hedging activities, have been allocated on a pro-rata basis using the deemed acquisition cost of FDAH as a percentage of the total acquisition cost of Wyeth. No other allocations of debt have been made as none are specifically related to our operations.
	The allocated expenses from Pfizer include the items noted below for the pre-Separation period in 2013 and the three and nine months ended September 30, 2012.
	•	Enabling Functions operating expenses––$11 million in 2013 and $77 million and $229 million in the three and nine months ended September 30, 2012, respectively ($1 million in the nine months ended September 30, 2012 in Cost of sales; $11 million in 2013 and $62 million and $185 million in the three and nine months ended September 30, 2012, respectively, in Selling, general and administrative expenses; and $15 million and $43 million in the three and nine months ended September 30, 2012, respectively, in Research and development expenses).
	•	PGS manufacturing costs—approximately $2 million and $14 million in the three and nine months ended September 30, 2012, respectively (in Cost of sales).
	•	Restructuring charges and certain acquisition-related costs—$12 million and $47 million in the three and nine months ended September 30, 2012, respectively (in Restructuring charges and certain acquisition-related costs).
	•	Other costs associated with cost reduction/productivity initiatives—additional depreciation associated with asset restructuring—$2 million in 2013 (in Selling, general and administrative expenses) and $1 million and $10 million in the three and nine months ended September 30, 2012, respectively (in Research and development expenses).
	•	Other costs associated with cost reduction/productivity initiatives—implementation costs—$1 million in 2013 and $2 million and $4 million in the three and nine months ended September 30, 2012, respectively (in Selling, general and administrative expenses).
	•	Share-based compensation expense—approximately $3 million in 2013 and $6 million and $22 million in the three and nine months ended September 30, 2012, respectively ($1 million in 2013 and $3 million and $5 million in the three and nine months ended September 30, 2012, respectively, in Cost of sales; $2 million in 2013 and $3 million and $14 million in the three and nine months ended September 30, 2012, respectively, in Selling, general and administrative expenses; and $3 million in the nine months ended September 30, 2012 in Research and development expenses).
	•	Compensation-related expenses—approximately $1 million in 2013 and $5 million and $16 million in the three and nine months ended September 30, 2012, respectively ($2 million and $5 million in the three and nine months ended September 30, 2012, respectively, in Cost of sales; $1 million in 2013 and $2 million and $7 million in the three and nine months ended September 30, 2012, respectively, in Selling, general and administrative expenses; and $1 million and $4 million in the three and nine months ended September 30, 2012, respectively, in Research and development expenses).
	•	Interest expense—approximately $2 million in 2013 and $7 million and $23 million in the three and nine months ended September 30, 2012, respectively.
	The income tax provision in the condensed combined statement of income was calculated as if Zoetis filed a separate return.
	Management believes that the allocations are a reasonable reflection of the services received or the costs incurred on behalf of Zoetis and its operations and that the condensed combined statement of income for the three and nine months ended ended September 30, 2012 and the pre-Separation period included in the condensed consolidated statement of income for the nine months ended September 29, 2013.
	Prior to the Separation, we participated in Pfizer's centralized cash management system and generally all excess cash was transferred to Pfizer on a daily basis. Cash disbursements for operations and/or investing activities were funded as needed by Pfizer. We had also participated in Pfizer's centralized hedging and offsetting programs. As such, in the combined statement of income for the three and nine months ended September 30, 2012, we include the impact of Pfizer's derivative financial instruments used for offsetting changes in foreign currency rates, net of the related foreign exchange gains and losses for the portion that is deemed to be associated with the animal health operations. Such gains and losses were not material to the combined financial statement for the periods presented.
	As of December 31, 2012, all balances and transactions among Zoetis and Pfizer and its subsidiaries, which can include dividends as well as other activities, are shown in Business unit equity in the combined balance sheet. As the books and records of Zoetis were not kept on a separate company basis, the determination of the average net balance due to or from Pfizer is not practicable.
	B.	Basis of Presentation After the Separation
	The unaudited condensed consolidated financial statements as of and for the three and nine months ended September 29, 2013 comprise the following: (i) the results of operations, comprehensive income, and cash flow amounts for the period prior to the Separation (see above), which includes allocations for direct costs and indirect costs attributable to the operations of the animal health business; and (ii) the amounts for the period after the Separation, which reflect the results of operations, comprehensive income, financial position, equity and cash flows resulting from our operation as a standalone public company.
	The income tax provision prepared after the Separation is based on the actual legal entity structure of Zoetis, with certain accommodations pursuant to a tax matters agreement. For additional information, see Note 17B. Transactions and Agreements with Pfizer: Agreements with Pfizer.

Significant_Accounting_Policie

Significant Accounting Policies	9 Months Ended
	Sep. 29, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	Significant Accounting Policies
	A.	New Accounting Standards
	There were no new accounting standards adopted during the first nine months of 2013.
	B.	Fair Value
	Our fair value methodologies depend on the following types of inputs:
	•	Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).
	•	Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).
	•	Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).
	A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.

Restructuring_Charges_and_Othe

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	9 Months Ended
	Sep. 29, 2013
Restructuring and Related Activities [Abstract]	'
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	'
	Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
	We incurred significant costs in connection with Pfizer’s cost-reduction initiatives (several programs initiated since 2005), and the acquisitions of Fort Dodge Animal Health (FDAH) on October 15, 2009 and King Animal Health (KAH) on January 31, 2011.
	For example:
	•	in connection with the cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems; and
	•	in connection with our acquisition activity, we typically incur costs and charges associated with executing the transactions, integrating the acquired operations, which may include expenditures for consulting and the integration of systems and processes, and restructuring the consolidated company, which may include charges related to employees, assets and activities that will not continue in the consolidated company.
	All operating functions can be impacted by these actions, including sales and marketing, manufacturing and research and development, as well as functions such as business technology, shared services and corporate operations.
	The components of costs incurred in connection with our acquisitions and restructuring initiatives follow:
			Three Months Ended						Nine Months Ended
			September 29,			September 30,			September 29,			September 30,
	(MILLIONS OF DOLLARS)		2013			2012			2013			2012
	Restructuring charges and certain acquisition-related costs:
	Integration costs(a)		$	3		$	6		$	16		$	15
	Restructuring charges (benefits)(b):
	Employee termination costs		—			(13		)	(26		)	(10		)
	Asset impairment charges		—			1			—			2
	Exit costs		—			—			—			1
	Total direct		3			(6		)	(10		)	8
	Integration costs(a)		—			4			—			16
	Restructuring charges(b):
	Employee termination costs		—			5			—			19
	Asset impairment charges		—			—			—			8
	Exit costs		—			3			—			4
	Total allocated		—			12			—			47
	Total Restructuring charges and certain acquisition-related costs		3			6			(10		)	55
	Other costs associated with cost-reduction/productivity initiatives:
	Additional depreciation associated with asset restructuring––direct(c)		—			5			1			10
	Additional depreciation associated with asset restructuring––allocated(c)		—			1			2			10
	Implementation costs––allocated(d)		—			2			1			4
	Total costs associated with acquisitions and cost-reduction/productivity initiatives		$	3		$	14		$	(6	)	$	79
	(a)	Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes.
	(b)	The restructuring benefit for the nine months ended September 29, 2013 is related to the reversal of certain employee termination expenses associated with our operations in Europe. In the fourth quarter of 2012, when we were a business unit of Pfizer, we announced a restructuring plan related to our operations in Europe. In connection with these actions, we recorded a pre-tax charge of $27 million to recognize employee termination costs. As a result of becoming a standalone public company (no longer being a majority-owned subsidiary of Pfizer) and related economic consideration, we revisited this restructuring action and decided to no longer implement this restructuring plan. As such, we reversed the existing reserve of $27 million in the second quarter of 2013. The restructuring benefits for the three and nine months ended September 30, 2012 are primarily related to the sale of a manufacturing plant.
	The direct restructuring charges (benefits) are associated with the following:
	•	For the nine months ended September 29, 2013––Manufacturing/research/corporate ($26 million income).
	•	For the three months ended September 30, 2012—EuAfME ($3 million) and manufacturing/research/corporate ($15 million income).
	•	For the nine months ended September 30, 2012––U.S. ($3 million), EuAfME ($2 million), CLAR ($1 million), and manufacturing/research/corporate ($13 million income, resulting from the sale of a manufacturing plant).
	(c)	Additional depreciation associated with asset restructuring represents the impact of changes in the estimated lives of assets involved in restructuring actions. For the nine months ended September 29, 2013, included in Cost of sales ($1 million) and Selling, general and administrative expenses ($2 million). For the three months ended September 30, 2012, included in Cost of sales ($4 million), Selling, general and administrative expenses ($1 million) and Research and development expenses ($1 million). For the nine months ended September 30, 2012, included in Cost of sales ($9 million), Selling, general and administrative expenses ($1 million) and Research and development expenses ($10 million).
	(d)	Implementation costs—allocated represent external, incremental costs directly related to implementing cost reduction/productivity initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services. Included in Selling, general and administrative expenses.
	The components of and changes in our direct restructuring accruals follow:
			Employee			Asset
			Termination			Impairment			Exit
	(MILLIONS OF DOLLARS)		Costs			Charges			Costs			Accrual
	Balance, December 31, 2012(a)		$	68		$	—		$	6		$	74
	Provision/(Benefit)		(26		)	—			—			(26		)
	Utilization and other(b)		(13		)	—			(4		)	(17		)
	Separation adjustment(c)		(14		)	—			—			(14		)
	Balance, September 29, 2013(a)		$	15		$	—		$	2		$	17
	(a)	At September 29, 2013 and December 31, 2012, included in Other current liabilities ($8 million and $63 million, respectively) and Other noncurrent liabilities ($9 million and $11 million, respectively).
	(b)	Includes adjustments for foreign currency translation.
	(c)	See Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.

Other_IncomeDeductions_Net

Other (Income)/Deductions - Net	9 Months Ended
	Sep. 29, 2013
Other Income and Expenses [Abstract]	'
Other (Income)/Deductions - Net	'
	Other (Income)/Deductions—Net
	The components of Other (income)/deductions—net follow:
			Three Months Ended						Nine Months Ended
			September 29,			September 30,			September 29,			September 30,
	(MILLIONS OF DOLLARS)		2013			2012			2013			2012
	Royalty-related income		$	(8	)	$	(11	)	$	(21	)	$	(24	)
	Identifiable intangible asset impairment charges(a)		—			2			1			5
	Net gain on sale of assets(b)		—			—			(6		)	—
	Certain legal matters, net(c)		1			—			1			(19		)
	Foreign currency (gain)/loss(d)		—			(1		)	12			2
	Other, net		1			(1		)	2			(1		)
	Other (income)/deductions—net		$	(6	)	$	(11	)	$	(11	)	$	(37	)
	(a)	For the nine months ended September 30, 2012, the intangible asset impairment charges include (i) approximately $2 million of finite-lived companion animal developed technology rights; (ii) approximately $1 million of finite-lived trademarks related to genetic testing services; and (iii) approximately $2 million of finite-lived patents related to poultry technology. These intangible asset impairment charges reflect, among other things, loss of revenue as a result of negative market conditions and, with respect to the poultry technology, a re-assessment of economic viability.
	(b)	For the nine months ended September 29, 2013, represents the net gain on the government-mandated sale of certain product rights in Brazil that were acquired with the FDAH acquisition in 2009.
	(c)	For the nine months ended September 30, 2012, represents income from a favorable legal settlement related to an intellectual property matter ($14 million) and a change in estimate for an environmental-related reserve due to a favorable settlement ($7 million income) partially offset by litigation-related charges ($2 million).
	(d)	For the nine months ended September 29, 2013, primarily related to the Venezuela currency devaluation in February 2013.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 29, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	A.	Taxes on Income
	The effective tax rate was 29.2% for the third quarter of 2013, compared to 24.4% for the third quarter of 2012. The higher effective tax rate in the third quarter of 2013 compared to the third quarter of 2012 was primarily attributable to:
	•	a $29 million tax benefit during the third quarter of 2012 resulting from Pfizer's settlement with the U.S. Internal Revenue Service (IRS) with respect to the audits of the Pfizer Inc. tax returns for the years 2006 through 2008;
	partially offset by:
	•	incentive tax rulings in Belgium, effective December 31, 2012, and Singapore, effective October 29, 2012; and
	•	changes in the jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs.
	The effective tax rate was 29.3% for the first nine months of 2013, compared to 29.9% for the first nine months of 2012. The lower effective tax rate in the first nine months of 2013 compared to the first nine months of 2012 was primarily attributable to:
	•	the aforementioned incentive tax rulings and changes in the jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs; and
	•	a $2 million discrete income tax benefit during the first quarter of 2013 related to the 2012 U.S. research and development tax credit which was retroactively extended on January 3, 2013;
	partially offset by:
	•	the tax benefit resulting from the aforementioned $29 million IRS settlement in 2012.
	As of the Separation date, we operate under a new standalone legal entity structure. In connection with the Separation, adjustments have been made to the income tax accounts. See Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.
	B.	Tax Matters Agreement
	In connection with the Separation, we entered into a tax matters agreement with Pfizer that governs the parties' respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes. For additional information, see below and Note 17B. Transactions and Agreements with Pfizer: Agreements with Pfizer.
	In connection with this agreement and the Separation, the activity in our income tax accounts reflects Separation Adjustments, including significant adjustments to the deferred income tax asset and liability accounts and the tax liabilities associated with uncertain tax positions. For additional information, see below and Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.
	In general, under the agreement:
	•	Pfizer will be responsible for any U.S. federal, state, local or foreign income taxes and any U.S. state or local non-income taxes (and any related interest, penalties or audit adjustments and including those taxes attributable to our business) reportable on a consolidated, combined or unitary return that includes Pfizer or any of its subsidiaries (and us and/or any of our subsidiaries) for any periods or portions thereof ending on or prior to December 31, 2012. We will be responsible for the portion of any such taxes for periods or portions thereof beginning on or after January 1, 2013, as would be applicable to us if we filed the relevant tax returns on a standalone basis.
	•	We will be responsible for any U.S. federal, state, local or foreign income taxes and any U.S. state or local non-income taxes (and any related interest, penalties or audit adjustments) that are reportable on returns that include only us and/or any of our subsidiaries, for all tax periods whether before or after the completion of the Separation.
	•	Pfizer will be responsible for certain specified foreign taxes directly resulting from certain aspects of the Separation.
	We will not generally be entitled to receive payment from Pfizer in respect of any of our tax attributes or tax benefits or any reduction of taxes of Pfizer. Neither party's obligations under the agreement will be limited in amount or subject to any cap. The agreement also assigns responsibilities for administrative matters, such as the filing of returns, payment of taxes due, retention of records and conduct of audits, examinations or similar proceedings. In addition, the agreement provides for cooperation and information sharing with respect to tax matters.
	Pfizer will be primarily responsible for preparing and filing any tax return with respect to the Pfizer affiliated group for U.S. federal income tax purposes and with respect to any consolidated, combined, unitary or similar group for U.S. state or local or foreign income tax purposes or U.S. state or local non-income tax purposes that includes Pfizer or any of its subsidiaries, including those that also include us and/or any of our subsidiaries. We will generally be responsible for preparing and filing any tax returns that include only us and/or any of our subsidiaries.
	The party responsible for preparing and filing a given tax return will generally have exclusive authority to control tax contests related to any such tax return.
	C.	Deferred Taxes
	As of September 29, 2013, the total net deferred income tax liability of $137 million is included in Current deferred tax assets ($66 million), Noncurrent deferred tax assets ($70 million), Other current liabilities ($4 million) and Noncurrent deferred tax liabilities ($269 million).
	As of December 31, 2012, the total net deferred income tax liability of $8 million is included in Current deferred tax assets ($101 million), Noncurrent deferred tax assets ($216 million), Other current liabilities ($2 million) and Noncurrent deferred tax liabilities ($323 million).
	The significant increase in the total net deferred tax liability from December 31, 2012 to September 29, 2013 is primarily attributable to the Separation Adjustments, predominantly related to deferred tax assets associated with net operating loss/credit carry forwards and deferred tax liabilities associated with unremitted earnings that were retained by Pfizer. See Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.
	D.	Tax Contingencies
	As of September 29, 2013, the tax liabilities associated with uncertain tax positions of $38 million (exclusive of interest related to uncertain tax positions of $10 million) were included in Noncurrent deferred tax assets ($7 million) and Other taxes payable ($31 million).
	As of December 31, 2012, the tax liabilities associated with uncertain tax positions of $144 million (exclusive of interest related to uncertain tax positions of $17 million) were included in Noncurrent deferred tax assets ($6 million) and Other taxes payable ($138 million).
	The significant decrease in the tax liabilities associated with uncertain tax positions from December 31, 2012 to September 29, 2013 is primarily attributable to the Separation Adjustments predominantly related to liabilities retained by Pfizer. See Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.
	Our tax liabilities for uncertain tax positions relate primarily to issues common among multinational corporations. Any settlements or statute of limitations expirations could result in a significant decrease in our uncertain tax positions. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. We do not expect that within the next twelve months any of our uncertain tax positions could significantly decrease as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of uncertain tax positions and potential tax benefits may not be representative of actual outcomes, and any variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income/(Loss)	9 Months Ended
	Sep. 29, 2013
Equity [Abstract]	'
Accumulated Other Comprehensive Loss	'
	Accumulated Other Comprehensive Loss
	Changes, net of tax, in accumulated other comprehensive loss follow:
			Currency Translation						Accumulated
			Adjustment			Benefit Plans			Other
			Net Unrealized			Actuarial			Comprehensive
	(MILLIONS OF DOLLARS)		Losses			Gains/(Losses)			Loss
	Balance, December 31, 2012		$	(152	)	$	(5	)	$	(157	)
	Other comprehensive loss, net of tax		(79		)	(3		)	(82		)
	Separation adjustments(a)		(7		)	1			(6		)
	Balance, September 29, 2013		$	(238	)	$	(7	)	$	(245	)
	(a)	See Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.

Financial_Instruments

Financial Instruments	9 Months Ended
	Sep. 29, 2013
Financial Instruments [Abstract]	'
Financial Instruments	'
	Financial Instruments
	A.	Credit Facilities
	In December 2012, we entered into a revolving credit agreement with a syndicate of banks providing for a five-year $1.0 billion senior unsecured revolving credit facility (the credit facility), which became effective in February 2013 upon the completion of the IPO and expires in December 2017. The credit facility contains a financial covenant requiring us to not exceed a maximum total leverage ratio (the ratio of consolidated net debt as of the end of the period to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (EBITDA) for such period) of 4.35:1 for fiscal year 2013, 3.95:1 for fiscal year 2014, 3.50:1 for fiscal year 2015 and 3.00:1 thereafter. The credit facility also contains a financial covenant requiring that we maintain a minimum interest coverage ratio (the ratio of EBITDA at the end of the period to interest expense for such period) of 3.50:1. In addition, the credit facility contains other customary covenants. Subject to certain conditions, we have the right to increase the credit facility to up to $1.5 billion. There are currently no borrowings outstanding.
	We have additional lines of credit with a group of banks and other financial intermediaries for general corporate purposes. We maintain cash and cash equivalent balances in excess of our outstanding short-term borrowings. As of September 29, 2013, we had access to $125 million of lines of credit which expire at various times through 2016. As of September 29, 2013, we had $10 million of short-term borrowings outstanding and $2 million of long-term borrowings outstanding related to these facilities.
	B.	Commercial Paper Program
	In February 2013, we entered into a commercial paper program with a capacity of up to $1.0 billion. As of September 29, 2013, no commercial paper has been issued under this program.
	C.	Short-Term Borrowings
	There were short-term borrowings of $10 million as of September 29, 2013 (see A. Credit Facilities). As of December 31, 2012 the current portion of allocated debt from Pfizer was $73 million. The weighted-average interest rate on short-term borrowings outstanding, including the current portion of allocated debt, was 5.4% and 3.7% as of September 29, 2013 and December 31, 2012, respectively.
	D.	Senior Notes Offering and Other Long-Term Debt
	On January 28, 2013, we issued $3.65 billion aggregate principal amount of our senior notes (the senior notes offering) in a private placement, with an original issue discount of $10 million. The senior notes are comprised of $400 million aggregate principal amount of our 1.150% senior notes due 2016, $750 million aggregate principal amount of our 1.875% senior notes due 2018, $1.35 billion aggregate principal amount of our 3.250% senior notes due 2023 and $1.15 billion aggregate principal amount of our 4.700% senior notes due 2043.
	We sold $2.65 billion aggregate principal amount of our senior notes through the initial purchasers in the senior notes offering and Pfizer transferred $1.0 billion aggregate principal amount of our senior notes to certain of the initial purchasers, who sold such senior notes in the senior notes offering.
	The senior notes are governed by an indenture and supplemental indenture (collectively, the indenture) between us and Deutsche Bank Trust Company Americas, as trustee. The indenture contains certain covenants, including limitations on our and certain of our subsidiaries' ability to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets. In addition, the indenture contains other customary terms, including certain events of default, upon the occurrence of which the senior notes may be declared immediately due and payable.
	Pursuant to the indenture, we are able to redeem the senior notes, in whole or in part, at any time by paying a “make whole” premium, plus accrued and unpaid interest to, but excluding, the date of redemption. Pursuant to our tax matters agreement with Pfizer, we will not be permitted to redeem the 2023 notes pursuant to this optional redemption provision, except under limited circumstances. Upon the occurrence of a change of control of us and a downgrade of the senior notes below an investment grade rating by each of Moody's Investors Service, Inc. and Standard & Poor's Ratings Services, we are, in certain circumstances, required to make an offer to repurchase all of the outstanding senior notes at a price equal to 101% of the aggregate principal amount of the senior notes together with accrued and unpaid interest to, but excluding, the date of repurchase.
	In connection with the senior notes offering, we entered into a registration rights agreement (Registration Rights Agreement) with the representatives of the initial purchasers of the senior notes.  Pursuant to the terms of the Registration Rights Agreement, we were obligated, among other things, to use our commercially reasonable efforts to file a registration statement with the SEC enabling holders of the senior notes to exchange the privately placed notes for publicly registered notes with substantially the same terms. We filed the registration statement with the SEC on September 13, 2013, the SEC declared the registration statement effective on September 24, 2013, and the exchange offer was completed on October 31, 2013.
	The components of our long-term debt follow:
			September 29,			December 31,
	(MILLIONS OF DOLLARS)		2013			2012
	Allocated long-term debt		$	—		$	509
	Lines of credit		2			—
	1.150% Senior Notes due 2016		400			—
	1.875% Senior Notes due 2018		750			—
	3.250% Senior Notes due 2023		1,350			—
	4.700% Senior Notes due 2043		1,150			—
			3,652			509
	Unamortized debt discount		(10		)	—
	Long-term debt / Allocated long-term debt		$	3,642		$	509
	As of September 29, 2013, the fair value of our long-term debt was $3,502 million and has been determined using a third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and Zoetis’s credit rating (Level 2 inputs). At December 31, 2012, the fair value of our allocated long-term debt was $732 million, and has been determined using a third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and Pfizer’s credit rating (Level 2 inputs). See Note 4B. Significant Accounting Policies: Fair Value. The fair value of the allocated long-term debt as of December 31, 2012 does not purport to reflect the fair value that might have been determined if Zoetis had operated as a standalone public company for the periods presented or if we had used Zoetis’s credit rating in the calculation.
	The principal amount of long-term debt outstanding as of September 29, 2013 matures in the following years:
														After
	(MILLIONS OF DOLLARS)		2014			2015		2016		2017		2018		2018		Total
	Maturities		$	—		$	—	$	401	$	1	$	750	$	2,500	$	3,652
	E.	Derivative Financial Instruments
	Foreign Exchange Risk
	A significant portion of our revenue, earnings and net investment in foreign affiliates is exposed to changes in foreign exchange rates. Prior to the IPO, as a business unit of Pfizer and under Pfizer's global cash management system, our foreign exchange risk was managed through Pfizer. Following the Separation, we seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenue in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk is also managed through the use of derivative financial instruments. These financial instruments serve to protect net income against the impact of the translation into U.S. dollars of certain foreign exchange-denominated transactions. As of September 29, 2013, the aggregate notional amount of foreign exchange derivative financial instruments offsetting foreign currency exposures was $1.5 billion. The derivative financial instruments primarily offset exposures in the euro, the Brazilian real and the Australian dollar. The vast majority of the foreign exchange derivative financial instruments mature within 60 days and all mature within 180 days.
	All derivative contracts used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the condensed consolidated balance sheet. The company has not designated the foreign currency forward-exchange contracts as hedging instruments. We recognize the gains and losses on forward-exchange contracts that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement.
	Fair Value of Derivative Instruments
	The location and fair values of derivative instruments not designated as hedging instruments at September 29, 2013 are as follows:
			Fair Value of
	(MILLIONS OF DOLLARS)	Balance Sheet Location	Derivatives
	Foreign currency forward-exchange contracts	Other current assets	$	6
	Foreign currency forward-exchange contracts	Other current liabilities	(1		)
	Total foreign currency forward-exchange contracts		$	5
	We use a market approach in valuing financial instruments on a recurring basis. Our derivative financial instruments measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value. See Note 4B. Significant Accounting Policies: Fair Value.
	The net gains incurred on foreign currency forward-exchange contracts not designated as hedging instruments were $13 million and $32 million for the three and nine months ended September 29, 2013, respectively, and are recorded in Other (income)/deductions—net. These amounts were substantially offset in Other (income)/deductions—net by the effect of changing exchange rates on the underlying foreign currency exposures.

Inventories

Inventories	9 Months Ended
	Sep. 29, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	The components of inventory follow:
		September 29,		December 31,
	(MILLIONS OF DOLLARS)	2013		2012
	Finished goods	$	887	$	799
	Work-in-process	203		332
	Raw materials and supplies	200		214
	Inventories	$	1,290	$	1,345

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	9 Months Ended
	Sep. 29, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangible Assets	'
	Goodwill and Other Intangible Assets
	A.	Goodwill
	The components of, and changes in, the carrying amount of goodwill follow:
	(MILLIONS OF DOLLARS)		U.S.			EuAfME			CLAR			APAC			Total
	Balance, December 31, 2012		$	502		$	157		$	163		$	163		$	985
	Other(a)		(2		)	(1		)	(1		)	(1		)	(5		)
	Balance, September 29, 2013		$	500		$	156		$	162		$	162		$	980
	(a)	Primarily reflects adjustments for foreign currency translation.
	The gross goodwill balance was $1,516 million as of September 29, 2013 and $1,521 million as of December 31, 2012. Accumulated goodwill impairment losses (generated entirely in fiscal 2002) were $536 million as of September 29, 2013 and December 31, 2012.
	B.	Other Intangible Assets
	The components of identifiable intangible assets follow:
			As of September 29, 2013									As of December 31, 2012
									Identifiable									Identifiable
									Intangible									Intangible
			Gross						Assets, Less			Gross						Assets, Less
			Carrying			Accumulated			Accumulated			Carrying			Accumulated			Accumulated
	(MILLIONS OF DOLLARS)		Amount			Amortization			Amortization			Amount			Amortization			Amortization
	Finite-lived intangible assets:
	Developed technology rights		$	761		$	(207	)	$	554		$	762		$	(173	)	$	589
	Brands		216			(97		)	119			216			(88		)	128
	Trademarks and trade names		53			(37		)	16			54			(36		)	18
	Other		122			(116		)	6			122			(115		)	7
	Total finite-lived intangible assets		1,152			(457		)	695			1,154			(412		)	742
	Indefinite-lived intangible assets:
	Brands		39			—			39			39			—			39
	Trademarks and trade names		67			—			67			67			—			67
	In-process research and development		14			—			14			20			—			20
	Total indefinite-lived intangible assets		120			—			120			126			—			126
	Identifiable intangible assets		$	1,272		$	(457	)	$	815		$	1,280		$	(412	)	$	868
	C.	Amortization
	Amortization expense related to acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as it benefits multiple business functions. Amortization expense related to acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, general and administrative expenses or Research and development expenses, as appropriate. Total amortization expense for finite-lived intangible assets was $16 million for both the three months ended September 29, 2013 and September 30, 2012, and $47 million and $51 million for the nine months ended September 29, 2013 and September 30, 2012, respectively.

Benefit_Plans

Benefit Plans	9 Months Ended
	Sep. 29, 2013
Compensation and Retirement Disclosure [Abstract]	'
Benefit Plans	'
	Benefit Plans
	Prior to the Separation from Pfizer, employees who met certain eligibility requirements participated in various defined benefit pension plans and postretirement plans administered and sponsored by Pfizer. Effective December 31, 2012, our employees ceased to participate in the Pfizer U.S. qualified defined benefit and U.S. retiree medical plans, and liabilities associated with our employees under these plans were retained by Pfizer. Pfizer is continuing to credit certain employees' service with Zoetis generally through December 31, 2017 (or termination of employment from Zoetis, if earlier) for certain early retirement benefits with respect to Pfizer's U.S. defined benefit pension and retiree medical plans. In connection with the employee matters agreement, Zoetis will be responsible for payment of three-fifths of the total cost of the service credit continuation (approximately $38 million) for these plans and Pfizer will fund the remaining two-fifths of the total cost (approximately $25 million). The $25 million capital contribution from Pfizer and corresponding contra-equity account (which will be reduced as the service credit continuation is incurred), is included in Employee benefit plan contribution from Pfizer Inc. in the Condensed Consolidated and Combined Statements of Equity at September 29, 2013. The amount of the service cost continuation payment to be paid by Zoetis to Pfizer was determined and fixed based on an actuarial assessment of the value of the grow-in benefits and will be paid in equal installments over a period of ten years. Pension and postretirement benefit expense associated with the extended service for certain employees in the U.S. plans totaled approximately $1 million and $5 million for the three and nine months ended September 29, 2013, respectively.
	Prior to the Separation from Pfizer, employees in the U.S. who met certain eligibility requirements participated in a supplemental (non-qualified) savings plan sponsored by Pfizer. In the second quarter of 2013, Pfizer transferred the supplemental savings plan liability of approximately $14 million, cash of $9 million and a deferred tax asset of $5 million associated with employees transferred to us.
	As part of the Separation, certain Separation Adjustments (see Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation) were made to transfer the assets and liabilities of certain international defined benefit pension plans including Austria, France, Germany, Greece, Italy, Mexico, South Africa, Taiwan and Thailand, to Zoetis in the first quarter of 2013, and we assumed the liabilities allocable to employees transferring to us. Prior to the Separation, these benefit plans were accounted for as multi-employer plans. Also, as part of the Separation Adjustments, a benefit plan in Germany was retained by Pfizer. The net obligation of the transferred plans totaled $25 million. At September 29, 2013, the projected benefit obligation and fair value of plan assets of the dedicated international pension plans in the Netherlands, Germany, India and Korea, as well as those plans transferred in the first quarter of 2013, were $74 million and $45 million, respectively. In the second quarter of 2013, a net liability of approximately $16 million was recognized for the pension obligations less the fair value of plan assets associated with additional defined benefit pension plans in certain international locations that will be transferred to us in 2014, in accordance with the applicable local separation agreements.
	Pension expense associated with dedicated international pension plans was approximately $1 million and $3 million for the three and nine months ended September 29, 2013, respectively. Pension expense associated with international benefit plans accounted for as multi-employer plans was approximately $2 million and $7 million for the three and nine months ended September 29, 2013, respectively.
	Contributions to the dedicated international benefits plans for the three and nine months ended September 29, 2013 were $1 million and $2 million, respectively. Contributions to the international plans accounted for as multi-employer plans for the three and nine months ended September 29, 2013 were $1 million and $6 million, respectively. We expect to contribute a total of approximately $9 million to these plans in 2013.

Sharebased_Payments

Share-based Payments	9 Months Ended
	Sep. 29, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Share-based Payments	'
	Share-Based Payments
	A.	Zoetis 2013 Equity and Incentive Plan
	In January 2013, the Zoetis 2013 Equity and Incentive Plan (Equity Plan) became effective. The principal types of stock-based awards available under the Equity Plan may include, but are not limited to, the following:
	•	Stock Options. Stock options represent the right to purchase shares of our common stock within a specified period of time at a specified price. The exercise price for a stock option will be not less than 100% of the fair market value of the common stock on the date of grant. Stock options will have a contractual maximum term of ten years from the date of grant. Stock options granted may include those intended to be “incentive stock options” within the meaning of Section 422 of the U.S. Internal Revenue Code of 1986 (the Code).
	•	Restricted Stock and Restricted Stock Units (RSUs). Restricted stock is a share of our common stock that is subject to a risk of forfeiture or other restrictions that will lapse subject to the recipient's continued employment, the attainment of performance goals, or both. Restricted stock units represent the right to receive shares of our common stock in the future (or cash determined by reference to the value of our common stock), subject to the recipient's continued employment, the attainment of performance goals, or both.
	•	Deferred Stock Unit Awards (DSUs). Deferred stock unit awards, which are granted to non-employee Directors, represent the right to receive shares of our common stock at a future date. The DSU awards will be automatically settled and paid in shares (including fractional shares), within sixty days following the non-employee Director’s separation of service on the Board of Directors.
	•	Performance-Based Awards. Performance awards will require satisfaction of pre-established performance goals, consisting of one or more business criteria and a targeted performance level with respect to such criteria as a condition of awards vesting or being settled. Performance may be measured over a period of any length specified but not less than one year.
	•	Other Equity-Based or Cash-Based Awards. Our Compensation Committee is authorized to grant awards in the form of other equity-based awards or other cash-based awards, as deemed to be consistent with the purposes of the Equity Plan. The maximum value of the aggregate payment to be paid to any participant with respect to cash-based awards under the Equity Plan in respect of an annual performance period will be $10 million.
	In order to provide long-term incentives to, and facilitate the retention of, our employees, we granted stock options (or other awards as appropriate with respect to our employees in non-U.S. jurisdictions) and/or restricted stock units under the Equity Plan on January 31, 2013 and February 1, 2013, respectively, to 1,700 of our employees. These awards will vest on the applicable three year anniversary date.
	B.	Share-Based Compensation Expense
	The components of share-based compensation expense follow:
			Three Months Ended						Nine Months Ended
			September 29,			September 30,			September 29,			September 30,
	(MILLIONS OF DOLLARS)		2013			2012			2013			2012
	Stock option expense		$	3		$	—		$	7		$	—
	RSU / DSU expense		3			—			5			—
	Pfizer stock benefit plans—direct		—			6			25			18
	Share-based compensation expense—direct		6			6			37			18
	Share-based compensation expense—indirect		—			—			—			4
	Share-based compensation expense—total		$	6		$	6		$	37		$	22
	C.	Stock Options
	Stock options are accounted for using a fair-value-based method at the date of grant in the consolidated statement of income. The values determined through this fair-value-based method generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.
	Eligible employees may receive Zoetis stock option grants. Zoetis stock options granted vest after three years of continuous service from the grant date and have a contractual term of 10 years.
	The fair-value-based method for valuing each Zoetis stock option grant on the grant date uses the Black-Scholes-Merton option-pricing model, which incorporates a number of valuation assumptions noted in the following table, shown at their weighted-average values:
			Nine Months Ended
			September 29, 2013
	Expected dividend yield(a)		1	%
	Risk-free interest rate(b)		1.3	%
	Expected stock price volatility(c)		28.21	%
	Expected term(d) (years)		6.5
	(a)	Determined using a constant dividend yield during the expected term of the Zoetis stock option.
	(b)	Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
	(c)	Determined using implied volatility.
	(d)	Determined using expected exercise and post-vesting termination patterns.
	The following table provides an analysis of stock option activity for the nine months ended September 29, 2013:
								Weighted-Average
					Weighted-Average			Remaining		Aggregate
					Exercise Price			Contractual Term		Intrinsic Value(a)
			Shares		Per Share			(Years)		(MILLIONS)
	Outstanding, December 31, 2012		—		$	—
	Granted		2,994,295		26.11
	Exercised		(6,419	)	26
	Forfeited		(60,559	)	26.02
	Outstanding, September 29, 2013		2,927,317		$	26.11		9.4		$	15
	Exercisable, September 29, 2013		4,992		$	26		9.3		—
	(a)	Market price of underlying Zoetis common stock less exercise price.
	The following table summarizes data related to stock option activity:
			Nine Months
			Ended/As of
	(MILLIONS OF DOLLARS, EXCEPT PER STOCK OPTION AMOUNTS)		September 29, 2013
	Weighted-average grant date fair value per stock option		$	7.05
	Total compensation cost related to nonvested stock options not yet recognized, pre-tax		$	14
	Weighted-average period over which stock option compensation is expected to be recognized (years)		2
	D.	Restricted Stock Units (RSUs)
	RSUs are accounted for using a fair-value-based method that utilizes the closing price of Zoetis common stock on the date of grant. In general, RSUs vest after three years of continuous service from the grant date and the values are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.
	The following table provides an analysis of RSU activity for the nine months ended September 29, 2013:
					Weighted-Average
					Grant Date
					Fair Value
			Shares		Per Share
	Nonvested, December 31, 2012		—		$	—
	Granted		979,611		26.81
	Vested		(661	)	26
Reinvested dividend equivalents		3,314		26.16
Forfeited		(19,890	)	26.23
Nonvested, September 29, 2013		962,374		$	26.82
The follow table provides data related to RSU activity:
		Nine Months
		Ended/As of
(MILLIONS OF DOLLARS)		September 29, 2013
Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax		$	21
Weighted-average period over which RSU cost is expected to be recognized (years)		2.3
E.	Deferred Stock Units (DSUs)
DSUs are accounted for using a fair-value-based method that utilizes the closing price of Zoetis common stock on the date of grant. DSUs vest immediately as of the grant date and the values are expensed at the time of grant into Selling, general and administrative expenses.
For the nine months ended September 29, 2013, Zoetis granted 34,804 DSUs at a grant date weighted-average fair value of $28.15 per stock unit. There were 34,870 DSUs outstanding, including dividend equivalents, as of September 29, 2013.
F.	Treatment of Outstanding Pfizer Equity Awards
Following the IPO, the equity awards previously granted to our employees by Pfizer continued to vest, and service with Zoetis counted as service with Pfizer for equity award purposes. On June 24, 2013, Pfizer completed the Exchange Offer whereby Pfizer disposed of all of its shares of Zoetis common stock owned by Pfizer. Pfizer accelerated the vesting of, and in some cases the settlement of, on a pro-rata basis, outstanding Pfizer RSUs, Total Shareholder Return Units (TSRUs) and Performance Share Awards (PSAs) previously granted to our employees, subject, in each case, to the requirements of Section 409A of the U.S. Internal Revenue Code, the terms of the 2004 Pfizer Stock Plan and the applicable award agreements and any outstanding deferral elections. In addition, unvested Pfizer stock options previously granted to our employees accelerated in full, and our employees generally have the ability to exercise the stock options until the earlier of (i) June 23, 2016 (three years from Pfizer's completion of the Exchange Offer), (ii) termination of employee from Zoetis, or (iii) the expiration date of the stock option. Zoetis employees who held Pfizer stock options and were retirement eligible as of June 24, 2013 will have the full term of the stock option to exercise.
The accelerated vesting of the outstanding Pfizer stock options, and the settlement, on a pro-rata basis, of other Pfizer equity awards, resulted in the recognition of additional expense for the nine months ended September 29, 2013 of $9 million, which is included in stock-based compensation. The unvested portion of Pfizer RSUs, TSRUs and PSAs were forfeited as of the completion of the Exchange Offer. In the third quarter of 2013, Zoetis made a cash payment of approximately $20 million to certain non-executive Zoetis employees, based on the value of the employees' forfeited Pfizer RSUs, TSRUs and PSAs (as applicable). This amount is included in the condensed consolidated statements of income as additional compensation expense for the nine months ended September 29, 2013. Members of the Zoetis Executive Team did not receive a cash payment for any forfeited Pfizer RSUs, TSRUs and PSAs, but instead, in the third quarter of 2013, they were granted Zoetis RSUs which were equivalent in value and vest on the same date as their forfeited Pfizer RSUs, TSRUs and PSAs.

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Sep. 29, 2013
Earnings Per Share [Abstract]	'
Earnings per Share	'
	Earnings per Share
	The following table presents the calculation of basic and diluted earnings per share:
		Three Months Ended					Nine Months Ended
		September 29,		September 30,			September 29,		September 30,
	(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA)	2013		2012			2013		2012
	Numerator
	Net income before allocation to noncontrolling interests	$	131	$	161		$	399	$	446
	Less: net income attributable to noncontrolling interests	—		(1		)	—		—
	Net income attributable to Zoetis Inc.	$	131	$	162		$	399	$	446
	Denominator
	Weighted-average common shares outstanding	500		500			500		500
	Common stock equivalents: stock options, RSUs and DSUs	0.354		—			0.227		—
	Weighted-average common and potential dilutive shares outstanding	500.354		500			500.227		500
	Earnings per share attributable to Zoetis Inc. stockholders—basic	$	0.26	$	0.32		$	0.8	$	0.89
	Earnings per share attributable to Zoetis Inc. stockholders—diluted	$	0.26	$	0.32		$	0.8	$	0.89

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 29, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see Note 7. Income Taxes.
	A.	Legal Proceedings
	Our non-tax contingencies include, among others, the following:
	•	Product liability and other product-related litigation, which can include injury, consumer, off-label promotion, antitrust and breach of contract claims.
	•	Commercial and other matters, which can include product-pricing claims and environmental claims and proceedings.
	•	Patent litigation, which typically involves challenges to the coverage and/or validity of our patents or those of third parties on various products or processes.
	•	Government investigations, which can involve regulation by national, state and local government agencies in the United States and in other countries.
	Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial.
	We believe that we have strong defenses in these types of matters, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations or cash flows in the period in which the amounts are paid.
	We have accrued for losses that are both probable and reasonably estimable. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.
	Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
	The principal matters to which we are a party are discussed below. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be a class action and our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information about the company that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters, we consider, among other things, the financial significance of the product protected by the patent.
	Roxarsone®(3-Nitro)
	We are defendants in nine actions involving approximately 140 plaintiffs that allege that the distribution of the medicated feed additive Roxarsone allegedly caused various diseases in the plaintiffs, including cancers and neurological diseases. Other defendants, including various poultry companies, are also named in these lawsuits. Compensatory and punitive damages are sought in unspecified amounts.
	In September 2006, the Circuit Court of Washington County returned a defense verdict in one of the lawsuits, Mary Green, et al. v. Alpharma, Inc. et al. In 2008, this verdict was appealed and affirmed by the Arkansas Supreme Court. Certain summary judgments favoring the poultry company co-defendants in Mary Green, et al. v. Alpharma, Inc. et al. were reversed by the Arkansas Supreme Court in 2008. These claims were retried in 2009 and that trial also resulted in a defense verdict, which was affirmed by the Arkansas Supreme Court in April 2011. In October 2012, we entered into an agreement to resolve these cases. The resolution is subject to the execution of full releases or dismissals with prejudice by all of the claimants or our waiver of these requirements. The trial schedule has been suspended pending the outcome of the proposed settlement.
	In June 2011, we announced that we would suspend sales in the U.S. of Roxarsone (3-Nitro) in response to a request by the U.S. FDA and subsequently stopped sales in several international markets.
	Following our decision to suspend sales of Roxarsone (3-Nitro) in June 2011, Zhejiang Rongyao Chemical Co., Ltd., the supplier of certain materials used in the production of Roxarsone (3-Nitro), filed a lawsuit in the U.S. District Court for the District of New Jersey alleging that we are liable for damages it suffered as a result of the decision to suspend sales. No trial date has been set and the parties are exploring possible settlement.
	PregSure®
	We have received in total approximately 80 claims in Europe and New Zealand seeking damages related to calves claimed to have died of Bovine Neonatal Pancytopenia (BNP) on farms where PregSure BVD, a vaccine against Bovine Virus Diarrhea (BVD) was used. BNP is a rare syndrome that first emerged in cattle in Europe in 2006. Studies of BNP suggest a potential association between the administration of PregSure and the development of BNP, although no causal connection has been established. The cause of BNP is not known.
	In 2010, we voluntarily stopped sales of PregSure BVD in Europe, and recalled the product at wholesalers while investigations into possible causes of BNP continue. In 2011, after incidences of BNP were reported in New Zealand, we voluntarily withdrew the marketing authorization for PregSure throughout the world.
	We have settled approximately 20 of these claims for amounts that are not material individually or in the aggregate. Investigations into possible causes of BNP continue and these settlements may not be representative of any future claims resolutions.
	Advocin
	On January 30, 2012, Bayer filed a complaint against Pfizer alleging infringement and inducement of infringement of Bayer patent US 5,756,506 covering, among other things, a process for treating bovine respiratory disease (BRD) by administering a single high dose of fluoroquinolone. The complaint was filed after Pfizer's product Advocin® was approved as a single dose treatment of BRD, in addition to its previous approval as a multi-dose treatment of BRD. Bayer seeks a permanent injunction, damages and a recovery of attorney's fees, and has demanded a jury trial. Discovery has now concluded. We have filed motions for summary judgment of non-infringement and invalidity of the Bayer patent, which are currently pending before the Court.
	Ulianopolis, Brazil
	In February 2012, the Municipality of Ulianopolis (State of Para, Brazil) filed a complaint against Fort Dodge Saúde Animal Ltda. (FDSAL) and five other large companies alleging that waste sent to a local waste incineration facility for destruction, but that was not ultimately destroyed as the facility lost its operating permit, caused environmental impacts requiring cleanup.
	The Municipality is seeking recovery of cleanup costs purportedly related to FDSAL's share of all waste accumulated at the incineration facility awaiting destruction, and compensatory damages to be allocated among the six defendants. We believe we have strong arguments against the claim, including defense strategies against any claim of joint and several liability.
	At the request of the Municipal prosecutor, in April 2012, the lawsuit was suspended for one year. Since that time, the prosecutor has initiated investigations into the Municipality's actions in the matter as well as the efforts undertaken by the six defendants to remove and dispose of their individual waste from the incineration facility.
	In early August 2013, new labor claims were filed against FDSAL as well as 57 other companies. These claims were filed by 30 employees of the local waste incineration facility that was used by FDSAL and the 57 other companies. The employees of the incineration facility allege health injuries in connection with their employment at the waste site. Based on legal precedent, it is possible that FDSAL may be considered a liable party. Due to the fact that we are in the early stages of discovery, the amount of a potential loss, if any, cannot be reasonably estimated. Counsel has advised that the likelihood of Zoetis being considered severally liable is remote.
	Other Matters
	The European Commission published a decision on alleged competition law infringements by several human health pharmaceutical companies on June 19, 2013. One of the involved legal entities is Zoetis Products LLC, formerly having the name Alpharma Inc. Zoetis Products LLC's involvement is solely related to its human health activities prior to Pfizer's acquisition of King/Alpharma. The fine imposed on Zoetis Products LLC amounts to Euro 11 million (approximately $14 million).  Under the Global Separation Agreement between Pfizer and Zoetis, Pfizer is obligated to indemnify Zoetis for any liabilities arising out of claims not related to its animal health assets. A liability of $14 million is included in Other current liabilities and a corresponding receivable from Pfizer of $14 million is included in Other current assets as of September 29, 2013. We filed an appeal of the decision on September 6, 2013.
	B.	Guarantees and Indemnifications
	In the ordinary course of business and in connection with the sale of assets and businesses, we indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of September 29, 2013, recorded amounts for the estimated fair value of these indemnifications are not significant.

Segment_and_Other_Revenue_Info

Segment and Other Revenue Information	9 Months Ended
	Sep. 29, 2013
Segment Reporting [Abstract]	'
Segment and Other Revenue Information	'
	Segment and Other Revenue Information
	A.	Segment Information
	The animal health medicines and vaccines industry is characterized by meaningful differences in customer needs across different regions. As a result of these differences, among other things, we manage our operations through four geographic regions. Each operating segment has responsibility for its commercial activities. Within each of these regional operating segments, we offer a diversified product portfolio, including vaccines, parasiticides, anti-infectives, medicated feed additives and other pharmaceuticals, for both livestock and companion animal customers.
	Operating Segments
	•	The United States (U.S.).
	•	Europe/Africa/Middle East (EuAfME)—Includes, among others, the United Kingdom, Germany, France, Italy, Spain, Northern Europe and Central Europe as well as Russia, Turkey and South Africa.
	•	Canada/Latin America (CLAR)––Includes Canada, Brazil, Mexico, Central America and Other South America.
	•	Asia/Pacific (APAC)––Includes Australia, Japan, New Zealand, South Korea, India, China/Hong Kong, Northeast Asia, Southeast Asia and South Asia.
	Our chief operating decision maker uses the revenue and earnings of the four operating segments, among other factors, for performance evaluation and resource allocation.
	Other Costs and Business Activities
	Certain costs are not allocated to our operating segment results, such as costs associated with the following:
	•	Research & development (R&D), which is generally responsible for research projects.
	•	Corporate, which is responsible for platform functions such as business technology, facilities, legal, finance, human resources, business development, public affairs and procurement, among others. These costs also include compensation costs and other miscellaneous operating expenses not charged to our operating segments, as well as interest income and expense.
	•	Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (ii) acquisition-related activities, where we incur costs for restructuring and integration; and (iii) certain significant items, which include non-acquisition-related restructuring charges, certain asset impairment charges and costs associated with cost reduction/productivity initiatives.
	Segment Assets
	We manage our assets on a total company basis, not by operating segment. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately $6.3 billion at both September 29, 2013 and December 31, 2012.
	Selected Statement of Income Information
													Depreciation and
			Revenue(a)				Earnings(b)						Amortization(c)
			September 29,		September 30,		September 29,			September 30,			September 29,		September 30,
	(MILLIONS OF DOLLARS)		2013		2012		2013			2012			2013		2012
	Three months ended
	U.S.		$	495	$	448	$	285		$	232		$	11	$	11
	EuAfME		270		241		92			91			5		9
	CLAR		171		165		56			53			5		5
	APAC		167		165		57			59			4		6
	Total reportable segments		1,103		1,019		490			435			25		31
	Other business activities(d)		—		—		(80		)	(65		)	6		4
	Reconciling Items:
	Corporate(e)		—		—		(139		)	(113		)	1		1
	Purchase accounting adjustments(f)		—		—		(12		)	(13		)	12		13
	Acquisition-related costs(g)		—		—		(1		)	(5		)	—		5
	Certain significant items(h)		—		—		(46		)	(11		)	—		—
	Other unallocated(i)		—		—		(27		)	(15		)	5		—
			$	1,103	$	1,019	$	185		$	213		$	49	$	54
	Nine Months Ended
	U.S.		$	1,386	$	1,294	$	773		$	676		$	33	$	26
	EuAfME		838		799		300			283			17		21
	CLAR		555		549		186			184			14		17
	APAC		528		518		203			193			10		13
	Total reportable segments		3,307		3,160		1,462			1,336			74		77
	Other business activities(d)		—		—		(228		)	(191		)	19		12
	Reconciling Items:
	Corporate(e)		—		—		(392		)	(346		)	16		18
	Purchase accounting adjustments(f)		—		—		(37		)	(39		)	37		39
	Acquisition-related costs(g)		—		—		(17		)	(34		)	—		10
	Certain significant items(h)		—		—		(130		)	(28		)	—		—
	Other unallocated(i)		—		—		(94		)	(62		)	5		—
			$	3,307	$	3,160	$	564		$	636		$	151	$	156
	(a)	Revenue denominated in euros were $159 million and $493 million in the three and nine months ended September 29, 2013, respectively and $142 million and $464 million in the three and nine months ended September 30, 2012, respectively.
	(b)	Defined as income before provision for taxes on income.
	(c)	Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
	(d)	Other business activities reflect the research and development costs managed by our Research and Development organization.
	(e)	Corporate includes, among other things, administration expenses, interest expense, certain compensation and other costs not charged to our operating segments.
	(f)	Purchase accounting adjustments include certain charges related to the fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.
	(g)	Acquisition-related costs can include costs associated with acquiring, integrating and restructuring acquired businesses, such as allocated transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring. For additional information, see Note 5. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.
	(h)	Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, the impact of divestiture-related gains and losses and certain costs related to becoming a standalone public company. For additional information, see Note 5. Restructuring Charges and Other Costs Associated with Acquisition and Cost-Reduction/Productivity Initiatives.
	•	In the third quarter of 2013, certain significant items primarily includes: (i) Zoetis stand-up costs of $41 million; and (ii) litigation-related charges of $5 million. Stand-up costs include certain nonrecurring costs related to becoming a standalone public company, such as new branding (including changes to the manufacturing process for required new packaging), the creation of standalone systems and infrastructure, site separation, accelerated vesting and associated cash payment related to certain Pfizer equity awards, and certain legal registration and patent assignment costs.
	•	In the third quarter of 2012, certain significant items includes: (i) charges related to transitional manufacturing purchase agreements associated with divestitures of $1 million and (ii) $10 million for restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition.
	•	In the nine months ended September 29, 2013, certain significant items primarily includes: (i) Zoetis stand-up costs of $152 million; (ii) $26 million income related to a reversal of certain employee termination expenses; (iii) $6 million income on the government-mandated sale of certain product rights in Brazil that were acquired with the FDAH acquisition in 2009; (iv) additional depreciation associated with asset restructuring of $3 million; and (v) litigation-related charges of $5 million.
	•	In the nine months ended September 30, 2012, certain significant items includes: (i) $14 million income related to a favorable legal settlement for an intellectual property matter; (ii) $4 million income due to a change in estimate related to transitional manufacturing purchase agreements associated with divestitures; and (iii) $46 million for restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition.
	(i)	Includes overhead expenses associated with our manufacturing operations.
	B.	Other Revenue Information
Revenue by Species
Significant species revenue are as follows:
		Three Months Ended				Nine Months Ended
		September 29,		September 30,		September 29,			September 30,
(MILLIONS OF DOLLARS)		2013		2012		2013			2012
Livestock:
Cattle		$	388	$	365	$	1,134		$	1,136
Swine		155		140		465			425
Poultry		134		125		404			375
Other		29		29		79			79
		706		659		2,082			2,015
Companion Animal:
Horses		37		35		124			130
Dogs and Cats		360		325		1,101			1,015
		397		360		1,225			1,145
Total revenue		$	1,103	$	1,019	$	3,307		$	3,160
Revenue by Major Product Category
Significant revenue by major product category are as follows:
		Three Months Ended				Nine Months Ended
		September 29,		September 30,		September 29,			September 30,
(MILLIONS OF DOLLARS)		2013		2012		2013			2012
Anti-infectives		$	333	$	299	$	920		$	882
Vaccines		298		266		877			812
Parasiticides		167		155		544			532
Medicated feed additives		93		105		294			298
Other pharmaceuticals		177		165		558			529
Other non-pharmaceuticals		35		29		114			107
Total revenue		$	1,103	$	1,019	$	3,307		$	3,160

Transactions_and_Agreements_wi

Transactions and Agreements with Pfizer	9 Months Ended
	Sep. 29, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Transactions and Agreements with Pfizer
	Zoetis had related party transactions with Pfizer through the completion of the Exchange Offer on June 24, 2013. As of the completion of the Exchange Offer, Pfizer is no longer a related party. Activities while Pfizer was a related party, as well as ongoing agreements with Pfizer, are detailed below.
	A.	Pre-Separation Period
	For the condensed combined statement of income for the three and nine months ended ended September 30, 2012, the costs of goods manufactured in manufacturing plants that were shared with other Pfizer business units was approximately $105 million and $320 million, respectively.
	In the pre-Separation period, Pfizer provided significant corporate, manufacturing and shared services functions and resources to us. Our condensed combined financial statements as of and for the three and nine months ended ended September 30, 2012, respectively, reflect an allocation of these costs. For further information about the cost allocations for these services and resources, see Note 3A. Basis of Presentation: Basis of Presentation Prior to the Separation. Management believes that these allocations are a reasonable reflection of the services received. However, these allocations may not reflect the expenses that would have been incurred if we had operated as a standalone public company for the period presented.
	Pfizer uses a centralized approach to cash management and financing its operations. In the pre-Separation period, cash deposits were remitted to Pfizer on a regular basis and were reflected in business unit equity and, similarly, Zoetis's cash disbursements were funded through Pfizer's cash accounts and were reflected within Business unit equity.
	B.	Agreements with Pfizer
	In connection with the Separation and IPO, we and Pfizer entered into agreements that provide a framework for our ongoing relationship with Pfizer, certain of which are described below.
	•	Global separation agreement. This agreement governs the relationship between Pfizer and us following the IPO and includes provisions related to the allocation of assets and liabilities, indemnification, delayed transfers and further assurances, mutual releases, insurance and certain covenants.
	•	Transitional services agreement. This agreement grants us the right to continue to use certain of Pfizer's services and resources related to our corporate functions, such as business technology, facilities, finance, human resources, public affairs and procurement, in exchange for mutually agreed-upon fees based on Pfizer's costs of providing these services.
	•	Tax matters agreement. This agreement governs ours and Pfizer's respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes. Pursuant to this agreement, we have also agreed to certain covenants that contain restrictions intended to preserve the tax-free status of certain transactions, and we have agreed to indemnify Pfizer and its affiliates against any and all tax-related liabilities incurred by them relating to these transactions to the extent caused by an acquisition of our stock or assets or by any other action undertaken by us.
	•	Research and development collaboration and license agreement. This agreement permits certain of our employees to be able to review a Pfizer database to identify compounds that may be of interest to the animal health field. Pfizer has granted to us an option to enter into a license agreement subject to certain restrictions and requirements and we will make payments to Pfizer.
	•	Employee matters agreement. This agreement governs ours and Pfizer's respective rights, responsibilities and obligations with respect to the following matters: employees and former employees (and their respective dependents and beneficiaries) who are or were associated with Pfizer, us or the parties' respective subsidiaries or affiliates; the allocation of assets and liabilities generally relating to employees, employment or service-related matters and employee benefit plans; and other human resources, employment and employee benefits matters.
	•	Master manufacturing and supply agreements. These two agreements govern our manufacturing and supply arrangements with Pfizer. Under one of these agreements, Pfizer will manufacture and supply us with animal health products. Under this agreement, our manufacturing and supply chain leadership will have oversight responsibility over product quality and other key aspects of the manufacturing process with respect to the Pfizer-supplied products. Under the other agreement, we will manufacture and supply certain human health products to Pfizer.
	•	Environmental matters agreement. This agreement governs the performance of remedial actions for liabilities allocated to each party under the global separation agreement; addresses our substitution for Pfizer with respect to animal health assets and remedial actions allocated to us (including substitution related to, for example, permits, financial assurances and consent orders); allows our conditional use of Pfizer's consultants and contractors to assist in the conduct of remedial actions; and addresses the exchange of related information between the parties. The agreement also sets forth standards of conduct for remedial activities at the co-located facilities: Guarulhos, Brazil; Catania, Italy; Hsinchu, Taiwan; and Kalamazoo, Michigan in the U.S. In addition, the agreement sets forth site-specific terms to govern conduct at several of these co-located facilities.
	•	Screening services agreement. This agreement requires us to provide certain high throughput screening services to Pfizer's R&D organization for which Pfizer pays to us agreed-upon fees.
	•	Intellectual property license agreements. Under these agreements (i) Pfizer and certain of its affiliates licensed to us and certain of our affiliates the right to use certain intellectual property rights in the animal health field; (ii) we licensed to Pfizer and certain of its affiliates certain rights to intellectual property in all fields outside of the animal health field; and (iii) Pfizer granted us rights with respect to certain trademarks and copyrighted works.
	Following the Separation, we own, have access to or have the right to use, substantially all of the resources that were used, or held for use, exclusively in Pfizer's animal health business, including the following:
	•	Intellectual Property. As part of the Separation, Pfizer assigned to us ownership of certain animal health related patents, pending patent applications, and trademark applications and registrations. In addition, Pfizer licensed to us the right to use certain intellectual property rights in the animal health field. We licensed to Pfizer the right to use certain of our trademarks and substantially all of our other intellectual property rights in the human health field and all other fields outside of animal health. In addition, Pfizer granted us a transitional license to use certain of Pfizer's trademarks and we granted Pfizer a transitional license to use certain of our trademarks for a period of time following the completion of the IPO.
	•	Manufacturing Facilities. Our global manufacturing network consists of 13 “anchor” manufacturing sites and 16 “satellite” manufacturing sites. Ownership of, or the existing leasehold interest in, these facilities were conveyed to us by Pfizer as part of the Separation. Among these 29 manufacturing sites is our facility in Guarulhos, Brazil, which we leased back to Pfizer. Certain of our products are currently manufactured at 14 manufacturing sites that were retained by Pfizer. The products manufactured by Pfizer at these sites and at our Guarulhos, Brazil facility continue to be supplied to us under the terms of a manufacturing and supply agreement we entered into with Pfizer.
	•	R&D Facilities. We have R&D operations co-located with certain of our manufacturing sites in Australia, Belgium, Brazil, Canada, China, Spain and the United States to facilitate the efficient transfer of production processes from our laboratories to manufacturing sites. In addition, we maintain R&D operations at non-manufacturing locations in Belgium, Brazil, India and the United States. As part of the Separation, Pfizer conveyed to us its interest in each of these R&D facilities, with the exception of our Mumbai, India facility, which we expect Pfizer to transfer to us after the completion of the Separation for cash consideration to be agreed upon, and, in the interim, we are leasing this facility from Pfizer.
	•	Employees. In general, as part of the Separation, employees of Pfizer who were substantially dedicated to the animal health business became our employees. However, labor and employment laws or other business considerations in some jurisdictions delayed Pfizer from transferring to us employees who are substantially dedicated to the animal health business. In those instances, to the extent permissible under applicable law, we and Pfizer entered into mutually-acceptable arrangements to provide for continued operation of the business until such time as the employees in those jurisdictions can be transferred to us.
	The amounts charged under each of the agreements with Pfizer, through the completion of the Exchange Offer on June 24, 2013, were as follows:
	(MILLIONS OF DOLLARS)
	Transitional services agreement		$	63
	Master manufacturing and supply agreements		130
	Employee matters agreement		99
	In certain jurisdictions, while the Zoetis entities obtain appropriate registration and licensing, Pfizer entities purchase product from Zoetis entities and resell such product to the local Zoetis entity at cost. This activity is reflected in Accounts receivable for the product Pfizer purchases from Zoetis entities and in Accounts payable for the product purchased from such Pfizer entities by our local Zoetis entity.
	We remained part of Pfizer's consolidated U.S. tax returns until we fully separated on June 24, 2013, and therefore reflected 2013 U.S. income taxes payable of $31 million as a payable to Pfizer in Other current liabilities.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 29, 2013
Accounting Policies [Abstract]	'
Fair Value	'
	Fair Value
	Our fair value methodologies depend on the following types of inputs:
	•	Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).
	•	Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).
	•	Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).
	A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.

Restructuring_Charges_and_Othe1

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)	9 Months Ended
	Sep. 29, 2013
Restructuring and Related Activities [Abstract]	'
Schedule of Costs Associated with Cost-Reduction/Productivity Initiatives and Acquisition Activity	'
	The components of costs incurred in connection with our acquisitions and restructuring initiatives follow:
			Three Months Ended						Nine Months Ended
			September 29,			September 30,			September 29,			September 30,
	(MILLIONS OF DOLLARS)		2013			2012			2013			2012
	Restructuring charges and certain acquisition-related costs:
	Integration costs(a)		$	3		$	6		$	16		$	15
	Restructuring charges (benefits)(b):
	Employee termination costs		—			(13		)	(26		)	(10		)
	Asset impairment charges		—			1			—			2
	Exit costs		—			—			—			1
	Total direct		3			(6		)	(10		)	8
	Integration costs(a)		—			4			—			16
	Restructuring charges(b):
	Employee termination costs		—			5			—			19
	Asset impairment charges		—			—			—			8
	Exit costs		—			3			—			4
	Total allocated		—			12			—			47
	Total Restructuring charges and certain acquisition-related costs		3			6			(10		)	55
	Other costs associated with cost-reduction/productivity initiatives:
	Additional depreciation associated with asset restructuring––direct(c)		—			5			1			10
	Additional depreciation associated with asset restructuring––allocated(c)		—			1			2			10
	Implementation costs––allocated(d)		—			2			1			4
	Total costs associated with acquisitions and cost-reduction/productivity initiatives		$	3		$	14		$	(6	)	$	79
	(a)	Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes.
	(b)	The restructuring benefit for the nine months ended September 29, 2013 is related to the reversal of certain employee termination expenses associated with our operations in Europe. In the fourth quarter of 2012, when we were a business unit of Pfizer, we announced a restructuring plan related to our operations in Europe. In connection with these actions, we recorded a pre-tax charge of $27 million to recognize employee termination costs. As a result of becoming a standalone public company (no longer being a majority-owned subsidiary of Pfizer) and related economic consideration, we revisited this restructuring action and decided to no longer implement this restructuring plan. As such, we reversed the existing reserve of $27 million in the second quarter of 2013. The restructuring benefits for the three and nine months ended September 30, 2012 are primarily related to the sale of a manufacturing plant.
	The direct restructuring charges (benefits) are associated with the following:
	•	For the nine months ended September 29, 2013––Manufacturing/research/corporate ($26 million income).
	•	For the three months ended September 30, 2012—EuAfME ($3 million) and manufacturing/research/corporate ($15 million income).
	•	For the nine months ended September 30, 2012––U.S. ($3 million), EuAfME ($2 million), CLAR ($1 million), and manufacturing/research/corporate ($13 million income, resulting from the sale of a manufacturing plant).
	(c)	Additional depreciation associated with asset restructuring represents the impact of changes in the estimated lives of assets involved in restructuring actions. For the nine months ended September 29, 2013, included in Cost of sales ($1 million) and Selling, general and administrative expenses ($2 million). For the three months ended September 30, 2012, included in Cost of sales ($4 million), Selling, general and administrative expenses ($1 million) and Research and development expenses ($1 million). For the nine months ended September 30, 2012, included in Cost of sales ($9 million), Selling, general and administrative expenses ($1 million) and Research and development expenses ($10 million).
	(d)	Implementation costs—allocated represent external, incremental costs directly related to implementing cost reduction/productivity initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services. Included in Selling, general and administrative expenses.
Schedule of Restructuring and Related Costs	'
	The components of and changes in our direct restructuring accruals follow:
			Employee			Asset
			Termination			Impairment			Exit
	(MILLIONS OF DOLLARS)		Costs			Charges			Costs			Accrual
	Balance, December 31, 2012(a)		$	68		$	—		$	6		$	74
	Provision/(Benefit)		(26		)	—			—			(26		)
	Utilization and other(b)		(13		)	—			(4		)	(17		)
	Separation adjustment(c)		(14		)	—			—			(14		)
	Balance, September 29, 2013(a)		$	15		$	—		$	2		$	17
	(a)	At September 29, 2013 and December 31, 2012, included in Other current liabilities ($8 million and $63 million, respectively) and Other noncurrent liabilities ($9 million and $11 million, respectively).
	(b)	Includes adjustments for foreign currency translation.
	(c)	See Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.

Other_IncomeDeductions_Net_Tab

Other (Income)/Deductions - Net (Tables)	9 Months Ended
	Sep. 29, 2013
Other Income and Expenses [Abstract]	'
Components of Other (Income)/DeductionsbNet	'
	The components of Other (income)/deductions—net follow:
			Three Months Ended						Nine Months Ended
			September 29,			September 30,			September 29,			September 30,
	(MILLIONS OF DOLLARS)		2013			2012			2013			2012
	Royalty-related income		$	(8	)	$	(11	)	$	(21	)	$	(24	)
	Identifiable intangible asset impairment charges(a)		—			2			1			5
	Net gain on sale of assets(b)		—			—			(6		)	—
	Certain legal matters, net(c)		1			—			1			(19		)
	Foreign currency (gain)/loss(d)		—			(1		)	12			2
	Other, net		1			(1		)	2			(1		)
	Other (income)/deductions—net		$	(6	)	$	(11	)	$	(11	)	$	(37	)
	(a)	For the nine months ended September 30, 2012, the intangible asset impairment charges include (i) approximately $2 million of finite-lived companion animal developed technology rights; (ii) approximately $1 million of finite-lived trademarks related to genetic testing services; and (iii) approximately $2 million of finite-lived patents related to poultry technology. These intangible asset impairment charges reflect, among other things, loss of revenue as a result of negative market conditions and, with respect to the poultry technology, a re-assessment of economic viability.
	(b)	For the nine months ended September 29, 2013, represents the net gain on the government-mandated sale of certain product rights in Brazil that were acquired with the FDAH acquisition in 2009.
	(c)	For the nine months ended September 30, 2012, represents income from a favorable legal settlement related to an intellectual property matter ($14 million) and a change in estimate for an environmental-related reserve due to a favorable settlement ($7 million income) partially offset by litigation-related charges ($2 million).
	(d)	For the nine months ended September 29, 2013, primarily related to the Venezuela currency devaluation in February 2013.

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income/(Loss) (Tables)	9 Months Ended
	Sep. 29, 2013
Equity [Abstract]	'
Changes, Net of Tax, in Accumulated Other Comprehensive Loss	'
	Changes, net of tax, in accumulated other comprehensive loss follow:
			Currency Translation						Accumulated
			Adjustment			Benefit Plans			Other
			Net Unrealized			Actuarial			Comprehensive
	(MILLIONS OF DOLLARS)		Losses			Gains/(Losses)			Loss
	Balance, December 31, 2012		$	(152	)	$	(5	)	$	(157	)
	Other comprehensive loss, net of tax		(79		)	(3		)	(82		)
	Separation adjustments(a)		(7		)	1			(6		)
	Balance, September 29, 2013		$	(238	)	$	(7	)	$	(245	)
	(a)	See Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.

Financial_Instruments_Tables

Financial Instruments (Tables)	9 Months Ended
	Sep. 29, 2013
Financial Instruments [Abstract]	'
Schedule of Long-term Debt Instruments	'
	The components of our long-term debt follow:
			September 29,			December 31,
	(MILLIONS OF DOLLARS)		2013			2012
	Allocated long-term debt		$	—		$	509
	Lines of credit		2			—
	1.150% Senior Notes due 2016		400			—
	1.875% Senior Notes due 2018		750			—
	3.250% Senior Notes due 2023		1,350			—
	4.700% Senior Notes due 2043		1,150			—
			3,652			509
	Unamortized debt discount		(10		)	—
	Long-term debt / Allocated long-term debt		$	3,642		$	509
Schedule of Maturities of Long-term Debt	'
	The principal amount of long-term debt outstanding as of September 29, 2013 matures in the following years:
														After
	(MILLIONS OF DOLLARS)		2014			2015		2016		2017		2018		2018		Total
	Maturities		$	—		$	—	$	401	$	1	$	750	$	2,500	$	3,652
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	'
	The location and fair values of derivative instruments not designated as hedging instruments at September 29, 2013 are as follows:
			Fair Value of
	(MILLIONS OF DOLLARS)	Balance Sheet Location	Derivatives
	Foreign currency forward-exchange contracts	Other current assets	$	6
	Foreign currency forward-exchange contracts	Other current liabilities	(1		)
	Total foreign currency forward-exchange contracts		$	5

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 29, 2013
Inventory Disclosure [Abstract]	'
Components of Inventory	'
	The components of inventory follow:
		September 29,		December 31,
	(MILLIONS OF DOLLARS)	2013		2012
	Finished goods	$	887	$	799
	Work-in-process	203		332
	Raw materials and supplies	200		214
	Inventories	$	1,290	$	1,345

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
	Sep. 29, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Changes in the Carrying Amount of Goodwill	'
	The components of, and changes in, the carrying amount of goodwill follow:
	(MILLIONS OF DOLLARS)		U.S.			EuAfME			CLAR			APAC			Total
	Balance, December 31, 2012		$	502		$	157		$	163		$	163		$	985
	Other(a)		(2		)	(1		)	(1		)	(1		)	(5		)
	Balance, September 29, 2013		$	500		$	156		$	162		$	162		$	980
	(a)	Primarily reflects adjustments for foreign currency translation.
Components of Identifiable Intangible Assets	'
	The components of identifiable intangible assets follow:
			As of September 29, 2013									As of December 31, 2012
									Identifiable									Identifiable
									Intangible									Intangible
			Gross						Assets, Less			Gross						Assets, Less
			Carrying			Accumulated			Accumulated			Carrying			Accumulated			Accumulated
	(MILLIONS OF DOLLARS)		Amount			Amortization			Amortization			Amount			Amortization			Amortization
	Finite-lived intangible assets:
	Developed technology rights		$	761		$	(207	)	$	554		$	762		$	(173	)	$	589
	Brands		216			(97		)	119			216			(88		)	128
	Trademarks and trade names		53			(37		)	16			54			(36		)	18
	Other		122			(116		)	6			122			(115		)	7
	Total finite-lived intangible assets		1,152			(457		)	695			1,154			(412		)	742
	Indefinite-lived intangible assets:
	Brands		39			—			39			39			—			39
	Trademarks and trade names		67			—			67			67			—			67
	In-process research and development		14			—			14			20			—			20
	Total indefinite-lived intangible assets		120			—			120			126			—			126
	Identifiable intangible assets		$	1,272		$	(457	)	$	815		$	1,280		$	(412	)	$	868

Sharebased_Payments_Tables

Share-based Payments (Tables)	9 Months Ended
	Sep. 29, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Components of Share-based Compensation Expense	'
	The components of share-based compensation expense follow:
			Three Months Ended						Nine Months Ended
			September 29,			September 30,			September 29,			September 30,
	(MILLIONS OF DOLLARS)		2013			2012			2013			2012
	Stock option expense		$	3		$	—		$	7		$	—
	RSU / DSU expense		3			—			5			—
	Pfizer stock benefit plans—direct		—			6			25			18
	Share-based compensation expense—direct		6			6			37			18
	Share-based compensation expense—indirect		—			—			—			4
	Share-based compensation expense—total		$	6		$	6		$	37		$	22
Share-based Payment Awards, Stock Options, Valuation Assumptions	'
	The fair-value-based method for valuing each Zoetis stock option grant on the grant date uses the Black-Scholes-Merton option-pricing model, which incorporates a number of valuation assumptions noted in the following table, shown at their weighted-average values:
			Nine Months Ended
			September 29, 2013
	Expected dividend yield(a)		1	%
	Risk-free interest rate(b)		1.3	%
	Expected stock price volatility(c)		28.21	%
	Expected term(d) (years)		6.5
	(a)	Determined using a constant dividend yield during the expected term of the Zoetis stock option.
	(b)	Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
	(c)	Determined using implied volatility.
	(d)	Determined using expected exercise and post-vesting termination patterns.
Stock Option Activity	'
	The following table provides an analysis of stock option activity for the nine months ended September 29, 2013:
								Weighted-Average
					Weighted-Average			Remaining		Aggregate
					Exercise Price			Contractual Term		Intrinsic Value(a)
			Shares		Per Share			(Years)		(MILLIONS)
	Outstanding, December 31, 2012		—		$	—
	Granted		2,994,295		26.11
	Exercised		(6,419	)	26
	Forfeited		(60,559	)	26.02
	Outstanding, September 29, 2013		2,927,317		$	26.11		9.4		$	15
	Exercisable, September 29, 2013		4,992		$	26		9.3		—
	(a)	Market price of underlying Zoetis common stock less exercise price.
	The following table summarizes data related to stock option activity:
			Nine Months
			Ended/As of
	(MILLIONS OF DOLLARS, EXCEPT PER STOCK OPTION AMOUNTS)		September 29, 2013
	Weighted-average grant date fair value per stock option		$	7.05
	Total compensation cost related to nonvested stock options not yet recognized, pre-tax		$	14
	Weighted-average period over which stock option compensation is expected to be recognized (years)		2
Restricted Stock Units (RSUs)	'
					Weighted-Average
					Grant Date
					Fair Value
			Shares		Per Share
	Nonvested, December 31, 2012		—		$	—
	Granted		979,611		26.81
	Vested		(661	)	26
	Reinvested dividend equivalents		3,314		26.16
	Forfeited		(19,890	)	26.23
	Nonvested, September 29, 2013		962,374		$	26.82
	The follow table provides data related to RSU activity:
			Nine Months
			Ended/As of
	(MILLIONS OF DOLLARS)		September 29, 2013
	Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax		$	21
	Weighted-average period over which RSU cost is expected to be recognized (years)		2.3

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Sep. 29, 2013
Earnings Per Share [Abstract]	'
Basic and Diluted Earnings Per Share	'
	The following table presents the calculation of basic and diluted earnings per share:
		Three Months Ended					Nine Months Ended
		September 29,		September 30,			September 29,		September 30,
	(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA)	2013		2012			2013		2012
	Numerator
	Net income before allocation to noncontrolling interests	$	131	$	161		$	399	$	446
	Less: net income attributable to noncontrolling interests	—		(1		)	—		—
	Net income attributable to Zoetis Inc.	$	131	$	162		$	399	$	446
	Denominator
	Weighted-average common shares outstanding	500		500			500		500
	Common stock equivalents: stock options, RSUs and DSUs	0.354		—			0.227		—
	Weighted-average common and potential dilutive shares outstanding	500.354		500			500.227		500
	Earnings per share attributable to Zoetis Inc. stockholders—basic	$	0.26	$	0.32		$	0.8	$	0.89
	Earnings per share attributable to Zoetis Inc. stockholders—diluted	$	0.26	$	0.32		$	0.8	$	0.89

Segment_and_Other_Revenue_Info1

Segment and Other Revenue Information (Tables)	9 Months Ended
	Sep. 29, 2013
Segment Reporting [Abstract]	'
Schedule of Selected Income Statement Information by Segment	'
													Depreciation and
			Revenue(a)				Earnings(b)						Amortization(c)
			September 29,		September 30,		September 29,			September 30,			September 29,		September 30,
	(MILLIONS OF DOLLARS)		2013		2012		2013			2012			2013		2012
	Three months ended
	U.S.		$	495	$	448	$	285		$	232		$	11	$	11
	EuAfME		270		241		92			91			5		9
	CLAR		171		165		56			53			5		5
	APAC		167		165		57			59			4		6
	Total reportable segments		1,103		1,019		490			435			25		31
	Other business activities(d)		—		—		(80		)	(65		)	6		4
	Reconciling Items:
	Corporate(e)		—		—		(139		)	(113		)	1		1
	Purchase accounting adjustments(f)		—		—		(12		)	(13		)	12		13
	Acquisition-related costs(g)		—		—		(1		)	(5		)	—		5
	Certain significant items(h)		—		—		(46		)	(11		)	—		—
	Other unallocated(i)		—		—		(27		)	(15		)	5		—
			$	1,103	$	1,019	$	185		$	213		$	49	$	54
	Nine Months Ended
	U.S.		$	1,386	$	1,294	$	773		$	676		$	33	$	26
	EuAfME		838		799		300			283			17		21
	CLAR		555		549		186			184			14		17
	APAC		528		518		203			193			10		13
	Total reportable segments		3,307		3,160		1,462			1,336			74		77
	Other business activities(d)		—		—		(228		)	(191		)	19		12
	Reconciling Items:
	Corporate(e)		—		—		(392		)	(346		)	16		18
	Purchase accounting adjustments(f)		—		—		(37		)	(39		)	37		39
	Acquisition-related costs(g)		—		—		(17		)	(34		)	—		10
	Certain significant items(h)		—		—		(130		)	(28		)	—		—
	Other unallocated(i)		—		—		(94		)	(62		)	5		—
			$	3,307	$	3,160	$	564		$	636		$	151	$	156
	(a)	Revenue denominated in euros were $159 million and $493 million in the three and nine months ended September 29, 2013, respectively and $142 million and $464 million in the three and nine months ended September 30, 2012, respectively.
	(b)	Defined as income before provision for taxes on income.
	(c)	Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
	(d)	Other business activities reflect the research and development costs managed by our Research and Development organization.
	(e)	Corporate includes, among other things, administration expenses, interest expense, certain compensation and other costs not charged to our operating segments.
	(f)	Purchase accounting adjustments include certain charges related to the fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.
	(g)	Acquisition-related costs can include costs associated with acquiring, integrating and restructuring acquired businesses, such as allocated transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring. For additional information, see Note 5. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.
	(h)	Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, the impact of divestiture-related gains and losses and certain costs related to becoming a standalone public company. For additional information, see Note 5. Restructuring Charges and Other Costs Associated with Acquisition and Cost-Reduction/Productivity Initiatives.
	•	In the third quarter of 2013, certain significant items primarily includes: (i) Zoetis stand-up costs of $41 million; and (ii) litigation-related charges of $5 million. Stand-up costs include certain nonrecurring costs related to becoming a standalone public company, such as new branding (including changes to the manufacturing process for required new packaging), the creation of standalone systems and infrastructure, site separation, accelerated vesting and associated cash payment related to certain Pfizer equity awards, and certain legal registration and patent assignment costs.
	•	In the third quarter of 2012, certain significant items includes: (i) charges related to transitional manufacturing purchase agreements associated with divestitures of $1 million and (ii) $10 million for restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition.
	•	In the nine months ended September 29, 2013, certain significant items primarily includes: (i) Zoetis stand-up costs of $152 million; (ii) $26 million income related to a reversal of certain employee termination expenses; (iii) $6 million income on the government-mandated sale of certain product rights in Brazil that were acquired with the FDAH acquisition in 2009; (iv) additional depreciation associated with asset restructuring of $3 million; and (v) litigation-related charges of $5 million.
	•	In the nine months ended September 30, 2012, certain significant items includes: (i) $14 million income related to a favorable legal settlement for an intellectual property matter; (ii) $4 million income due to a change in estimate related to transitional manufacturing purchase agreements associated with divestitures; and (iii) $46 million for restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition.
	(i)	Includes overhead expenses associated with our manufacturing operations.
Schedule of Significant Product Revenues	'
	Revenue by Species
	Significant species revenue are as follows:
			Three Months Ended				Nine Months Ended
			September 29,		September 30,		September 29,			September 30,
	(MILLIONS OF DOLLARS)		2013		2012		2013			2012
	Livestock:
	Cattle		$	388	$	365	$	1,134		$	1,136
	Swine		155		140		465			425
	Poultry		134		125		404			375
	Other		29		29		79			79
			706		659		2,082			2,015
	Companion Animal:
	Horses		37		35		124			130
	Dogs and Cats		360		325		1,101			1,015
			397		360		1,225			1,145
	Total revenue		$	1,103	$	1,019	$	3,307		$	3,160
	Revenue by Major Product Category
	Significant revenue by major product category are as follows:
			Three Months Ended				Nine Months Ended
			September 29,		September 30,		September 29,			September 30,
	(MILLIONS OF DOLLARS)		2013		2012		2013			2012
	Anti-infectives		$	333	$	299	$	920		$	882
	Vaccines		298		266		877			812
	Parasiticides		167		155		544			532
	Medicated feed additives		93		105		294			298
	Other pharmaceuticals		177		165		558			529
	Other non-pharmaceuticals		35		29		114			107
	Total revenue		$	1,103	$	1,019	$	3,307		$	3,160

Transactions_and_Agreements_wi1

Transactions and Agreements with Pfizer (Tables)	9 Months Ended
	Sep. 29, 2013
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions	'
	The amounts charged under each of the agreements with Pfizer, through the completion of the Exchange Offer on June 24, 2013, were as follows:
	(MILLIONS OF DOLLARS)
	Transitional services agreement	$	63
	Master manufacturing and supply agreements	130
	Employee matters agreement	99

Organization_Details

Organization (Details)	Sep. 29, 2013
	species
	product_categories
	region
	countries
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Number of regional segments	4
Number of countries in which entity markets products	120
Number of core animal species	8
Number of major product categories	5

Separation_Activities_and_Init1

Separation Activities and Initial Public Offering (Separation and Senior Notes Offering) (Details) (USD $)	Sep. 29, 2013	Jan. 28, 2013	Jan. 28, 2013	Jan. 28, 2013
		Senior Notes [Member]	Pfizer Transfer [Member]	Pfizer Transfer [Member]
				Senior Notes [Member]
Debt Instrument [Line Items]	'	'	'	'
Senior notes transferred to Pfizer	'	'	'	$1,000,000,000
Cash transferred to Pfizer	'	'	2,500,000,000	'
Debt, principal amount	3,652,000,000	3,650,000,000	'	1,000,000,000
Debt, unamortized discount	'	$10,000,000	'	'

Separation_Activities_and_Init2

Separation Activities and Initial Public Offering (Separation Adjustments) (Details) (Separation Adjustment [Member], USD $)	Jun. 24, 2013
In Millions, unless otherwise specified
Schedule of Separation Adjustments [Line Items]	'
Net liabilities retained by Pfizer	$450
Removal of property, plant and equipment, retained by Pfizer	2
Removal of net other assets, retained by Pfizer	5
Business Separation, Addition of Net Receivables, From Related Party	5
Addition of net benefit plan liabilities, retained by Pfizer	25
Elimination of noncurrent deferred tax assets, retained by Pfizer	49
Addition of noncurrent deferred tax assets, retained by Pfizer	8
Addition of noncurrent deferred tax assets related to net operating loss and tax credit carryforwards, retained by Pfizer	2
Addition of noncurrent deferred tax liabilities related to property, plant and equipment transferred by Pfizer	2
Elimination of allocated long-term debt, retained by Pfizer	582
Elimination of allocated accrued Interest payable, retained by Pfizer	16
Elimination of allocated unamortized deferred debt issuance costs, retained by Pfizer	2
Certain net financial assets retained by Pfizer	45
Removal of miscellaneous other liabilities, retained by Pfizer	57
Business Separation, Addition to Net Deferred Tax Assets, Adjustment	1
Business Separation, Addition to Inventory, Retained by Related Party	15
Business Separation, Elimination of Prepaid Taxes	4
Business Separation, Addition of Net Benefit Plan Liabilities, To Transfer from Related Party	16
Non-dedicated Manufacturing Sites Retained by Pfizer [Member]	'
Schedule of Separation Adjustments [Line Items]	'
Removal of inventories, retained by Pfizer	74
Removal of property, plant and equipment, retained by Pfizer	28
Removal of other net liabilities, retained by Pfizer	21
Non-dedicated Manufacturing Site Transferred by Pfizer [Member]	'
Schedule of Separation Adjustments [Line Items]	'
Removal of inventories, retained by Pfizer	46
Addition of property, plant and equipment, retained by Pfizer	56
Removal of net other assets, retained by Pfizer	4
Non U.S. Jurisdiction [Member]	'
Schedule of Separation Adjustments [Line Items]	'
Removal of inventories, retained by Pfizer	5
Removal of property, plant and equipment, retained by Pfizer	8
Removal of other net liabilities, retained by Pfizer	2
Business Separation, Decrease in Cash, Retained by Related Party	7
Removal of net other assets, retained by Pfizer	$3

Separation_Activities_and_Init3

Separation Activities and Initial Public Offering (Initial Public Offering) (Details) (USD $)	Sep. 29, 2013	Feb. 06, 2013	Feb. 06, 2013	Feb. 06, 2013
		Common Class A [Member]	Common Class B [Member]	IPO [Member]
				Common Class A [Member]
Class of Stock [Line Items]	'	'	'	'
Common stock, shares issued	500,006,833	'	'	99,015,000
Share price	'	'	'	$26
Common stock, shares outstanding	500,006,833	99,015,000	400,985,000	'

Basis_of_Presentation_Pre_IPO_

Basis of Presentation (Pre IPO Allocations) (Details) (USD $)

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Sep. 29, 2013

Sep. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Jan. 28, 2013

Sep. 30, 2012

Sep. 30, 2012

Jan. 28, 2013

Sep. 30, 2012

Sep. 30, 2012

Jan. 28, 2013

Sep. 30, 2012

Sep. 30, 2012

Sep. 30, 2012

Sep. 30, 2012

Sep. 30, 2012

Sep. 30, 2012

Allocated Expense From Parent [Member]

Allocated Expense From Parent [Member]

Allocated Expense From Parent [Member]

Allocated Expense From Parent [Member]

Allocated Expense From Parent [Member]

Allocated Expense From Parent [Member]

Allocated Expense From Parent [Member]

Allocated Expense From Parent [Member]

Allocated Expense From Parent [Member]

Allocated Expense From Parent [Member]

Allocated Expense From Parent [Member]

Allocated Expense From Parent [Member]

Allocated Expense From Parent [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Research and Development Expense [Member]

Research and Development Expense [Member]

Restructuring Charges and Certain Acquisition-related Costs [Member]

Restructuring Charges and Certain Acquisition-related Costs [Member]

Schedule of Expenses Allocated from Separation [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Enabling Functions operating expenses

'

'

'

'

$11

$77

$229

'

'

$1

$11

$62

$185

$15

$43

'

'

PGS manufacturing costs

'

'

'

'

'

'

'

'

2

14

'

'

'

'

'

'

'

Restructuring charges and certain acquisition-related costs

3

6

-10

55

'

'

'

'

'

'

'

'

'

'

'

12

47

Other costs associated with cost reduction/productivity initiativesbadditional depreciation associated with asset restructuring

'

'

'

'

'

'

'

'

'

'

2

'

'

1

10

'

'

Other costs associated with cost reduction/productivity initiativesbimplementation costs

'

'

'

'

'

'

'

'

'

'

1

2

4

'

'

'

'

Share-based compensation expense

6

6

37

18

3

6

22

1

3

5

2

3

14

'

3

'

'

Compensation-related expenses

'

'

'

'

1

5

16

'

2

5

1

2

7

1

4

'

'

Interest expense, net of capitalized interest

$29

$7

$83

$23

$2

$7

$23

'

'

'

'

'

'

'

'

'

'

Restructuring_Charges_and_Othe2

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Sep. 29, 2013

Sep. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Sep. 30, 2012

Sep. 30, 2012

Sep. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 29, 2013

Sep. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Sep. 30, 2012

Sep. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Sep. 30, 2012

Sep. 30, 2012

Sep. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Certain Significant Items [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Research and Development Expense [Member]

Research and Development Expense [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Certain Significant Items [Member]

Direct Cost [Member]

Direct Cost [Member]

Direct Cost [Member]

Direct Cost [Member]

Direct Cost [Member]

Direct Cost [Member]

Direct Cost [Member]

Direct Cost [Member]

Direct Cost [Member]

Direct Cost [Member]

Direct Cost [Member]

Allocated Cost [Member]

Allocated Cost [Member]

Allocated Cost [Member]

Allocated Cost [Member]

United States (U.S.) [Member]

Europe, Africa, and Middle East (EuAfME) [Member]

Europe, Africa, and Middle East (EuAfME) [Member]

Europe, Africa, and Middle East (EuAfME) [Member]

Canada and Latin America (CLAR) [Member]

Manufacturing, Research, Corporate [Member]

Manufacturing, Research, Corporate [Member]

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Integration costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3

[1]

$6

[1]

$16

[1]

$15

[1]

'

'

'

'

'

'

'

$0

[1]

$4

[1]

$0

[1]

$16

[1]

Restructuring Charges

'

'

-26

'

-26

'

'

'

'

'

'

'

'

27

'

[2]

'

[2]

'

[2]

'

3

3

26

2

1

15

13

'

[2]

'

[2]

'

[2]

'

[2]

Employee Termination Costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

[2]

-13

[2]

-26

[2]

-10

[2]

'

'

'

'

'

'

'

0

[2]

5

[2]

0

[2]

19

[2]

Asset Impairment Charges

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

[2]

1

[2]

0

[2]

2

[2]

'

'

'

'

'

'

'

0

[2]

0

[2]

0

[2]

8

[2]

Exit Costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

[2]

0

[2]

0

[2]

1

[2]

'

'

'

'

'

'

'

0

[2]

3

[2]

0

[2]

4

[2]

Total Restructuring charges and certain acquisition-related costs

3

6

-10

55

'

'

'

'

'

'

'

'

'

'

3

[3]

-6

[3]

-10

[3]

8

[3]

'

'

'

'

'

'

'

0

12

0

47

Additional depreciation associated with asset restructuring

'

'

'

'

3

[3]

4

1

9

1

10

1

2

1

'

0

[3]

5

[3]

1

[3]

10

[3]

'

'

'

'

'

'

'

0

[3]

1

[3]

2

[3]

10

[3]

Implementation costsbballocated(d)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

[4],[5]

2

[4],[5]

1

[4],[5]

4

[4],[5]

Total costs associated with acquisitions and cost-reduction/productivity initiatives

$3

$14

($6)

$79

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes.

[2]

The restructuring benefit for the nine months ended SeptemberB 29, 2013 is related to the reversal of certain employee termination expenses associated with our operations in Europe. In the fourth quarter of 2012, when we were a business unit of Pfizer, we announced a restructuring plan related to our operations in Europe. In connection with these actions, we recorded a pre-tax charge of $27 million to recognize employee termination costs. As a result of becoming a standalone public company (no longer being a majority-owned subsidiary of Pfizer) and related economic consideration, we revisited this restructuring action and decided to no longer implement this restructuring plan. As such, we reversed the existing reserve of $27 million in the second quarter of 2013. The restructuring benefits for the three and nine months ended SeptemberB 30, 2012 are primarily related to the sale of a manufacturing plant. The direct restructuring charges (benefits) are associated with the following: b"For the nine months ended SeptemberB 29, 2013bbManufacturing/research/corporate ($26 million income). b"For the three months ended SeptemberB 30, 2012bEuAfME ($3 million) and manufacturing/research/corporate ($15 million income). b"For the nine months ended SeptemberB 30, 2012bbU.S. ($3 million), EuAfME ($2 million), CLAR ($1 million), and manufacturing/research/corporate ($13 million income, resulting from the sale of a manufacturing plant).

[3]

Additional depreciation associated with asset restructuring represents the impact of changes in the estimated lives of assets involved in restructuring actions. For the nine months ended SeptemberB 29, 2013, included in Cost of sales ($1 million) and Selling, general and administrative expenses ($2 million). For the three months ended SeptemberB 30, 2012, included in Cost of sales ($4 million), Selling, general and administrative expenses ($1 million) and Research and development expenses ($1 million). For the nine months ended SeptemberB 30, 2012, included in Cost of sales ($9 million), Selling, general and administrative expenses ($1 million) and Research and development expenses ($10 million).

[4]

[5]

Implementation costsballocated represent external, incremental costs directly related to implementing cost reduction/productivity initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services. Included in Selling, general and administrative expenses.

Restructuring_Charges_and_Othe3

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Direct restructuring charges) (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013		Dec. 31, 2012
Restructuring Cost and Reserve	'		'
Balance, December 31, 2012(a)	$74	[1]	'
Provision/(Benefit)	-26		'
Utilization and other(b)	-17	[2]	'
Separation adjustment(c)	-14	[3]	'
Balance, September 29, 2013(a)	17	[1]	'
Restructuring Reserve, Current	8		63
Restructuring Reserve, Noncurrent	9		11
Employee Termination Costs [Member]	'		'
Restructuring Cost and Reserve	'		'
Balance, December 31, 2012(a)	68	[1]	'
Provision/(Benefit)	-26		'
Utilization and other(b)	-13	[2]	'
Separation adjustment(c)	-14	[3]	'
Balance, September 29, 2013(a)	15	[1]	'
Asset Impairments [Member]	'		'
Restructuring Cost and Reserve	'		'
Balance, December 31, 2012(a)	0	[1]	'
Provision/(Benefit)	0		'
Utilization and other(b)	0	[2]	'
Separation adjustment(c)	0	[3]	'
Balance, September 29, 2013(a)	0	[1]	'
Exit Costs [Member]	'		'
Restructuring Cost and Reserve	'		'
Balance, December 31, 2012(a)	6	[1]	'
Provision/(Benefit)	0		'
Utilization and other(b)	-4	[2]	'
Separation adjustment(c)	0	[3]	'
Balance, September 29, 2013(a)	$2	[1]	'
[1]	At SeptemberB 29, 2013 and DecemberB 31, 2012, included in Other current liabilities ($8 million and $63 million, respectively) and Other noncurrent liabilities ($9 million and $11 million, respectively)
[2]	Includes adjustments for foreign currency translation.
[3]	See Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.

Other_IncomeDeductions_Net_Det

Other (Income)/Deductions - Net (Details) (USD $)	3 Months Ended				9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013		Sep. 30, 2012		Sep. 29, 2013		Sep. 30, 2012
Other Income Deductions	'		'		'		'
Royalty-related income	($8)		($11)		($21)		($24)
Identifiable intangible asset impairment charges(a)	0		2		1		5
Net gain on sale of assets(b)	0	[1]	0	[1]	-6	[1]	0	[1]
Certain legal matters, net(c)	1	[2]	0	[2]	1	[2]	-19	[2]
Foreign currency (gain)/loss(d)	0	[3]	-1	[3]	12	[3]	2	[3]
Other, net	1		-1		2		-1
Nonoperating Income (Expense)	-6		-11		-11		-37
Gain (Loss) Related to Litigation Settlement	'		'		'		14
Other Increase (Decrease) in Environmental Liabilities	'		'		'		7
Legal Fees	'		'		'		2
Developed Technology Rights [Member]	'		'		'		'
Other Income Deductions	'		'		'		'
Identifiable intangible asset impairment charges(a)	'		'		'		2
Patented Technology [Member]	'		'		'		'
Other Income Deductions	'		'		'		'
Identifiable intangible asset impairment charges(a)	'		'		'		1
Patented Technology [Member]	'		'		'		'
Other Income Deductions	'		'		'		'
Identifiable intangible asset impairment charges(a)	'		'		'		$2
[1]	For the nine months ended SeptemberB 29, 2013, represents the net gain on the government-mandated sale of certain product rights in Brazil that were acquired with the FDAH acquisition in 2009.
[2]	For the nine months ended SeptemberB 30, 2012, represents income from a favorable legal settlement related to an intellectual property matter ($14 million) and a change in estimate for an environmental-related reserve due to a favorable settlement ($7 million income) partially offset by litigation-related charges ($2 million).
[3]	For the nine months ended SeptemberB 29, 2013, primarily related to the Venezuela currency devaluation in February 2013.

Income_Taxes_Taxes_on_Income_D

Income Taxes (Taxes on Income) (Details) (USD $)	3 Months Ended			9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013	Mar. 31, 2013	Sep. 30, 2012	Sep. 29, 2013	Sep. 30, 2012
Income Tax Disclosure [Abstract]	'	'	'	'	'
Effective tax rate for income from continuing operations	29.20%	'	24.40%	29.30%	29.90%
Tax Adjustments, Settlements, and Unusual Provisions	'	'	$29	'	'
Discrete income tax benefit, research and development tax credit	'	$2	'	'	'

Income_Taxes_Deferred_Taxes_De

Income Taxes (Deferred Taxes) (Details) (USD $)	Sep. 29, 2013		Dec. 31, 2012
In Millions, unless otherwise specified
Income Tax Disclosure [Abstract]	'		'
Net deferred income tax liability	$137		$8
Current deferred tax assets	66	[1]	101	[1]
Noncurrent deferred tax assets	70	[1]	216	[1]
Other current deferred liabilities	4		2
Noncurrent deferred tax liabilities	$269		$323
[1]	The condensed consolidated balance sheet as of September 29, 2013 has been prepared under a different basis of presentation than the condensed combined balance sheet as of December 31, 2012, which significantly impacts comparability. See Note 3. Basis of Presentation.

Income_Taxes_Tax_Contingencies

Income Taxes (Tax Contingencies) (Details) (USD $)	Sep. 29, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Income Tax Contingency [Line Items]	'	'
Unrecognized tax benefits	$38	$144
Unrecognized tax benefits, exclusive of interest related to unrecognized tax benefits	10	17
Noncurrent Deferred Tax Assets [Member]	'	'
Income Tax Contingency [Line Items]	'	'
Unrecognized tax benefits	7	6
Other Taxes Payable [Member]	'	'
Income Tax Contingency [Line Items]	'	'
Unrecognized tax benefits	$31	$138

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income/(Loss) (Details) (USD $)	3 Months Ended			9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013		Sep. 30, 2012	Sep. 29, 2013		Sep. 30, 2012
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'		'	'		'
Balance, December 31, 2012	'		'	($157)	[1]	'
Other comprehensive loss, net of tax	-62		24	-82		-104
Separation adjustments(a)	'		'	-6	[2]	'
Balance, September 29, 2013	-245	[1]	'	-245	[1]	'
Currency Translation Adjustment Net Unrealized Gain/(Losses) [Member]	'		'	'		'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'		'	'		'
Balance, December 31, 2012	'		'	-152		'
Other comprehensive loss, net of tax	'		'	-79		'
Separation adjustments(a)	'		'	-7	[2]	'
Balance, September 29, 2013	-238		'	-238		'
Benefit Plans Actuarial Gains/(Losses) [Member]	'		'	'		'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'		'	'		'
Balance, December 31, 2012	'		'	-5		'
Other comprehensive loss, net of tax	'		'	-3		'
Separation adjustments(a)	'		'	1	[2]	'
Balance, September 29, 2013	($7)		'	($7)		'
[1]	The condensed consolidated balance sheet as of September 29, 2013 has been prepared under a different basis of presentation than the condensed combined balance sheet as of December 31, 2012, which significantly impacts comparability. See Note 3. Basis of Presentation.
[2]	(a) See Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.

Financial_Instruments_Credit_F

Financial Instruments (Credit Facility) (Details) (USD $)	Sep. 29, 2013	Dec. 31, 2012
Line of Credit Facility [Line Items]	'	'
Long-term Line of Credit	$2,000,000	'
Line of credit facility, maximum borrowing capacity	125,000,000	'
Revolving credit facility, minimum interest coverage ratio	'	3.5
Line of Credit Facility, Amount Outstanding	0	'
Revolving Credit Facility [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Revolving credit facility, term	'	'5 years
Revolving credit facility, current borrowing capacity	'	1,000,000,000
Revolving credit facility, covenant compliance ratio, 2013	'	4.35
Revolving credit facility, covenant compliance ratio, 2014	'	3.95
Revolving credit facility, covenant compliance ratio, 2015	'	3.5
Revolving credit facility, covenant compliance ratio, 2016 and thereafter	'	3
Line of credit facility, maximum borrowing capacity	'	1,500,000,000

Financial_Instruments_Commerci

Financial Instruments (Commercial Paper) (Details) (USD $)	Sep. 29, 2013	Feb. 28, 2013
		Commercial Paper [Member]
Short-term Debt [Line Items]	'	'
Capacity of commercial paper program	'	$1,000,000,000
Commercial Paper	$0	'

Financial_Instruments_ShortTer

Financial Instruments (Short-Term Borrowings) (Details) (USD $)	Sep. 29, 2013		Dec. 31, 2012
In Millions, unless otherwise specified
Financial Instruments [Abstract]	'		'
Short-term Bank Loans and Notes Payable	$10		'
Short-term borrowings, carried at historical proceeds, as adjusted	$10	[1]	$73	[1]
Short-term debt, weighted-average effective interest rate	5.40%		3.70%
[1]	The condensed consolidated balance sheet as of September 29, 2013 has been prepared under a different basis of presentation than the condensed combined balance sheet as of December 31, 2012, which significantly impacts comparability. See Note 3. Basis of Presentation.

Financial_Instruments_Senior_N

Financial Instruments (Senior Notes Offering) (Details) (USD $)	Sep. 29, 2013	Jan. 28, 2013
In Millions, unless otherwise specified
Debt Instrument [Line Items]	'	'
Debt, principal amount	$3,652	'
Senior Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt, principal amount	'	3,650
Debt, unamortized discount	'	10
Debt, purchase price percent due to downgrade of investment grade	'	101.00%
Senior Notes [Member] | Initial Purchasers [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt, principal amount	'	2,650
Senior Notes [Member] | Pfizer Transfer [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt, principal amount	'	1,000
Senior Notes [Member] | Senior Notes 1.150% due 2016 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt, principal amount	400	400
Debt, stated interest rate	'	1.15%
Senior Notes [Member] | Senior Notes 1.875% due 2018 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt, principal amount	750	750
Debt, stated interest rate	'	1.88%
Senior Notes [Member] | Senior Notes 3.250% due 2023 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt, principal amount	1,350	1,350
Debt, stated interest rate	'	3.25%
Senior Notes [Member] | Senior Notes 4.700% due 2043 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt, principal amount	$1,150	$1,150
Debt, stated interest rate	'	4.70%

Financial_Instruments_Schedule

Financial Instruments (Schedule of Long-term Debt) (Details) (USD $)

Sep. 29, 2013

Dec. 31, 2012

Sep. 29, 2013

Jan. 28, 2013

Sep. 29, 2013

Jan. 28, 2013

Sep. 29, 2013

Jan. 28, 2013

Sep. 29, 2013

Jan. 28, 2013

Sep. 29, 2013

Jan. 28, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

In Millions, unless otherwise specified

Allocated Long-term Debt [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Senior Notes 1.150% due 2016 [Member]

Senior Notes 1.150% due 2016 [Member]

Senior Notes 1.875% due 2018 [Member]

Senior Notes 1.875% due 2018 [Member]

Senior Notes 3.250% due 2023 [Member]

Senior Notes 3.250% due 2023 [Member]

Senior Notes 4.700% due 2043 [Member]

Senior Notes 4.700% due 2043 [Member]

Allocated Long-term Debt [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes 1.150% due 2016 [Member]

Senior Notes 1.875% due 2018 [Member]

Senior Notes 3.250% due 2023 [Member]

Senior Notes 4.700% due 2043 [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total long-term debt

$3,652

'

$0

$3,650

$400

$400

$750

$750

$1,350

$1,350

$1,150

$1,150

$509

$509

$0

$0

$0

$0

Long-term Line of Credit, Noncurrent

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unamortized debt discount

-10

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

Long-term debt / Allocated long-term debt

$3,642

[1]

$0

[1]

'

'

'

'

'

'

'

'

'

'

$509

'

'

'

'

'

[1]

The condensed consolidated balance sheet as of September 29, 2013 has been prepared under a different basis of presentation than the condensed combined balance sheet as of December 31, 2012, which significantly impacts comparability. See Note 3. Basis of Presentation.

Financial_Instruments_Fair_Val

Financial Instruments (Fair Value of Debt) (Details) (Fair Value, Inputs, Level 2 [Member], USD $)	Sep. 29, 2013	Dec. 31, 2012
In Millions, unless otherwise specified	Senior Notes [Member]	Allocated Long-term Debt [Member]
Debt Instrument [Line Items]	'	'
Fair value, debt instrument	$3,502	$732

Financial_Instruments_Longterm

Financial Instruments (Long-term Debt Maturity) (Details) (USD $)	Sep. 29, 2013
In Millions, unless otherwise specified
Financial Instruments [Abstract]	'
2014	$0
2015	0
2016	401
2017	1
2018	750
After 2018	2,500
Total long-term debt	$3,652

Financial_Instruments_Foreign_

Financial Instruments Foreign Exchange Risk (Details) (Foreign Exchange Contract [Member], USD $)	9 Months Ended
In Billions, unless otherwise specified	Sep. 29, 2013
Foreign Exchange Contract [Member]	'
Derivative [Line Items]	'
Derivative, Notional Amount	1.5
Majority [Member] | Foreign Exchange Contract [Member]	'
Derivative [Line Items]	'
Derivative, Term of Contract	'60 days
Maximum [Member] | Foreign Exchange Contract [Member]	'
Derivative [Line Items]	'
Derivative, Term of Contract	'180 days

Financial_Instruments_Fair_Val1

Financial Instruments (Fair Value of Derivative Instruments) (Details) (Foreign Exchange Forward [Member], USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013	Sep. 29, 2013
Derivatives, Fair Value [Line Items]	'	'
Gain (loss) on derivative contracts not designated as hedging instruments	$13	$32
Not Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Total foreign currency forward-exchange contracts	5	5
Not Designated as Hedging Instrument [Member] | Other Current Assets [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Foreign currency forward-exchange contracts	6	6
Not Designated as Hedging Instrument [Member] | Other Current Liabilities [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Foreign currency forward-exchange contracts	($1)	($1)

Inventories_Details

Inventories (Details) (USD $)	Sep. 29, 2013		Dec. 31, 2012
In Millions, unless otherwise specified
Inventory Disclosure [Abstract]	'		'
Finished goods	$887		$799
Work-in-process	203		332
Raw materials and supplies	200		214
Inventories	$1,290	[1]	$1,345	[1]
[1]	The condensed consolidated balance sheet as of September 29, 2013 has been prepared under a different basis of presentation than the condensed combined balance sheet as of December 31, 2012, which significantly impacts comparability. See Note 3. Basis of Presentation.

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets (Goodwill) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013		Dec. 31, 2012
Goodwill [Roll Forward]	'		'
Balance, December 31, 2012	'		$985	[1]
Other(a)	-5	[2]	'
Balance, September 29, 2013	980	[1]	985	[1]
United States (U.S.) [Member]	'		'
Goodwill [Roll Forward]	'		'
Balance, December 31, 2012	'		502
Other(a)	-2	[2]	'
Balance, September 29, 2013	500		502
Europe, Africa, and Middle East (EuAfME) [Member]	'		'
Goodwill [Roll Forward]	'		'
Balance, December 31, 2012	'		157
Other(a)	-1	[2]	'
Balance, September 29, 2013	156		157
Canada and Latin America (CLAR) [Member]	'		'
Goodwill [Roll Forward]	'		'
Balance, December 31, 2012	'		163
Other(a)	-1	[2]	'
Balance, September 29, 2013	162		163
Asia Pacific (APAC) [Member]	'		'
Goodwill [Roll Forward]	'		'
Balance, December 31, 2012	'		163
Other(a)	-1	[2]	'
Balance, September 29, 2013	$162		$163
[1]	The condensed consolidated balance sheet as of September 29, 2013 has been prepared under a different basis of presentation than the condensed combined balance sheet as of December 31, 2012, which significantly impacts comparability. See Note 3. Basis of Presentation.
[2]	a)B Primarily reflects adjustments for foreign currency translation.

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets (Finite-lived and Indefinite-lived Intangible Assets) (Details) (USD $)	Sep. 29, 2013		Dec. 31, 2012
In Millions, unless otherwise specified
Finite Lived and Indefinite Lived Intangible Assets [Line Items]	'		'
Finite-lived intangible assets, Gross Carrying Amount	$1,152		$1,154
Finite-lived intangible assets, Accumulated Amortization	-457		-412
Finite-lived intangible assets, Identifiable Intangible Assets, Less Accumulated Amortization	695		742
Total indefinite-lived intangible assets	120		126
Intangible Assets, Gross Carrying Amount	1,272		1,280
Identifiable Intangible Assets, Less Accumulated Amortization	815	[1]	868	[1]
Brands [Member]	'		'
Finite Lived and Indefinite Lived Intangible Assets [Line Items]	'		'
Total indefinite-lived intangible assets	39		39
Trademarks and Trade Names [Member]	'		'
Finite Lived and Indefinite Lived Intangible Assets [Line Items]	'		'
Total indefinite-lived intangible assets	67		67
In Process Research And Development [Member]	'		'
Finite Lived and Indefinite Lived Intangible Assets [Line Items]	'		'
Total indefinite-lived intangible assets	14		20
Developed Technology Rights [Member]	'		'
Finite Lived and Indefinite Lived Intangible Assets [Line Items]	'		'
Finite-lived intangible assets, Gross Carrying Amount	761		762
Finite-lived intangible assets, Accumulated Amortization	-207		-173
Finite-lived intangible assets, Identifiable Intangible Assets, Less Accumulated Amortization	554		589
Brands [Member]	'		'
Finite Lived and Indefinite Lived Intangible Assets [Line Items]	'		'
Finite-lived intangible assets, Gross Carrying Amount	216		216
Finite-lived intangible assets, Accumulated Amortization	-97		-88
Finite-lived intangible assets, Identifiable Intangible Assets, Less Accumulated Amortization	119		128
Trademarks and Trade Names [Member]	'		'
Finite Lived and Indefinite Lived Intangible Assets [Line Items]	'		'
Finite-lived intangible assets, Gross Carrying Amount	53		54
Finite-lived intangible assets, Accumulated Amortization	-37		-36
Finite-lived intangible assets, Identifiable Intangible Assets, Less Accumulated Amortization	16		18
Other Intangible Assets [Member]	'		'
Finite Lived and Indefinite Lived Intangible Assets [Line Items]	'		'
Finite-lived intangible assets, Gross Carrying Amount	122		122
Finite-lived intangible assets, Accumulated Amortization	-116		-115
Finite-lived intangible assets, Identifiable Intangible Assets, Less Accumulated Amortization	$6		$7
[1]	The condensed consolidated balance sheet as of September 29, 2013 has been prepared under a different basis of presentation than the condensed combined balance sheet as of December 31, 2012, which significantly impacts comparability. See Note 3. Basis of Presentation.

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013	Sep. 30, 2012	Sep. 29, 2013	Sep. 30, 2012	Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'	'
Gross goodwill	$1,516	'	$1,516	'	$1,521
Accumulated goodwill impairment losses	536	'	536	'	536
Amortization expense for finite-lived intangible assets	$16	$16	$47	$51	'

Benefit_Plans_Details

Benefit Plans (Details) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013	Sep. 29, 2013	Dec. 31, 2012
U.S. Plan [Member]	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Total cost of the service credit continuation Zoetis will be responsible for	'	'	$38
Percentage of total cost of the service credit continuation Zoetis will be responsible for	'	'	60.00%
Payment term of the service cost continuation (in years)	'	'10 years	'
Pension and postretirement benefit expense	1	5	'
International Pension Plans [Member]	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Pension and postretirement benefit expense	1	3	'
Contributions to benefit plans	1	2	'
Foreign Pension Plans, Defined Benefit in Austria, France, Greece, Italy, Mexico, South Africa, Taiwan, Thailand, and Other [Member]	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Estimated net obligation	25	25	'
Foreign Pension Plans, Defined Benefit in the Netherlands, Germany, India, Korea, and Other [Member]	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Gross pension benefit obligation	74	74	'
Fair value of plan assets	45	45	'
International Pension Plans in Other Locations [Member]	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Estimated net obligation	16	16	'
Multi-employer Plan [Member]	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Pension and postretirement benefit expense	2	7	'
International Pension Plans Accounted for As Multi-employer Plans [Member]	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Contributions to benefit plans	1	6	'
Expected future contributions to benefit plans	'	9	'
Pfizer [Member] | U.S. Plan [Member]	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Total cost of the service credit continuation Pfizer will be responsible for	'	'	25
Description of total cost of the service credit continuation Pfizer will be responsible for	'	'	40.00%
Pfizer [Member] | Supplemental Saving Plan [Member]	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'
Supplemental savings plan liability transferred from Pfizer	14	'	'
Supplemental savings plan cash funding transferred from Pfizer	9	'	'
Supplemental savings plan associated tax asset transferred from Pfizer	$5	'	'

Sharebased_Payments_Narrative_

Share-based Payments (Narrative) (Details) (USD $)	Feb. 06, 2013	Sep. 29, 2013	Sep. 29, 2013	Sep. 29, 2013	Sep. 29, 2013	Sep. 29, 2013	Sep. 29, 2013
In Millions, except Share data, unless otherwise specified	employees	Stock Options [Member]	Restricted Stock Units (RSUs) [Member]	Deferred Stock Units (DSUs) [Member]	Pfizer Stock Benefit Plans [Member]	Other Equity-Based or Cash-Based Awards [Member]	Other Equity-Based or Cash-Based Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Granted (in shares)	'	'	979,611	34,804	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	'	'	$26.81	$28.15	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	'	'	-661	34,870	'	'	'
Exercise price percentage of the fair market value price at date of grant	'	100.00%	'	'	'	'	'
Contractual term	'	'10 years	'	'	'3 years 0 months 0 days	'	'
Maximum annual payment made to plan participant	'	'	'	'	'	'	$10
Number of employees	1,700	'	'	'	'	'	'
Award vesting period	'	'3 years	'3 years	'	'	'	'
Additional expense of accelerated vesting of the outstanding Pfizer stock options, and the settlement	'	'	'	'	'	9	'
Cash payment next quarter	'	'	'	'	'	$20	'

Sharebased_Payments_Components

Share-based Payments (Components of share-based compensation expense) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013	Sep. 30, 2012	Sep. 29, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based compensation expensebdirect	$6	$6	$37	$18
Share-based compensation expensebindirect	0	0	0	4
Share-based compensation expensebtotal	6	6	37	22
Stock Options [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based compensation expensebdirect	3	0	7	0
Restricted Stock Units (RSUs) [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based compensation expensebdirect	3	0	5	0
Pfizer Stock Benefit Plans [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based compensation expensebdirect	$0	$6	$25	$18

Sharebased_Payments_Stock_opti

Share-based Payments (Stock option valuation assumptions) (Details)	9 Months Ended
	Sep. 29, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Expected dividend yield(a)	1.00%	[1]
Risk-free interest rate(b)	1.30%	[2]
Expected stock price volatility(c)	28.21%	[3]
Expected term(d) (years)	'6 years 6 months	[4]
[1]	Determined using a constant dividend yield during the expected term of the Zoetis stock option.
[2]	Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
[3]	Determined using implied volatility.
[4]	Determined using expected exercise and post-vesting termination patterns.

Sharebased_Payments_Stock_opti1

Share-based Payments (Stock option activity) (Details) (USD $)	9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 29, 2013
Shares	'
Outstanding, December 31, 2012 (in shares)	0
Granted (in shares)	2,994,295
Forfeited (in shares)	-60,559
Outstanding, June 30, 2013 (in shares)	2,927,317
Exercisable, September 29, 2013	4,992
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$26
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	'9 years 4 months 0 days
Weighted-average Exercise Price Per Share	'
Outstanding, December 31, 2012 (in dollars per share)	$0
Granted (in dollars per share)	$26.11
Forfeited (in dollars per share)	$26.02
Outstanding, June 30, 2013 (in dollars per share)	$26.11
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	-6,419
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$26
Outstanding, Weighted-average Remaining Contractual Term	'9 years 5 months 0 days
Outstanding, Aggregate Intrinsic Value	$15	[1]
Vested and expected to vest, Weighted-average Remaining Contractual Term	'0 years
Vested and expected to vest, Aggregate Intrinsic Value	0	[1]
Weighted-average grant date fair value per stock option	$7.05
Stock Options [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Unrecognized compensation costs	$14
Unrecognized compensation costs, period for recognition	'2 years
[1]	Market price of underlying Zoetis common stock less exercise price.

Sharebased_Payments_Nonvested_

Share-based Payments (Nonvested restricted stock activity) (Details) (Restricted Stock Units (RSUs) [Member], USD $)	9 Months Ended
	Sep. 29, 2013
Restricted Stock Units (RSUs) [Member]	'
Shares	'
Nonvested, December 31, 2012 (in shares)	0
Granted (in shares)	979,611
Forfeited (in shares)	-19,890
Nonvested, June 30, 2013 (in shares)	962,374
Weighted Average Grant Date Fair Value Per Share	'
Nonvested, December 31, 2012 (in dollars per share)	$0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$26.81
Forfeited (in dollars per share)	$26.23
Nonvested, June 30, 2013 (in dollars per share)	$26.82
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	-661
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	$26
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Reinvested Dividend Equivalents In Period	$3,314
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Reinvested Dividend Equivalents Weighted Average Grant Date Fair Value	26.16
Unrecognized compensation costs	$21,000,000
Unrecognized compensation costs, period for recognition	'2 years 3 months 18 days

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Sep. 29, 2013	Sep. 30, 2012	Sep. 29, 2013	Sep. 30, 2012
Numerator	'	'	'	'
Net income before allocation to noncontrolling interests	$131	$161	$399	$446
Less: net income attributable to noncontrolling interests	0	-1	0	0
Net income attributable to Zoetis Inc.	$131	$162	$399	$446
Denominator	'	'	'	'
Weighted-average common shares outstanding	500,000	500,000	500,000	500,000
Common stock equivalents: stock options, RSUs and DSUs	354	0	227	0
Weighted-average common and potential dilutive shares outstanding	500,354	500,000	500,227	500,000
Earnings per share attributable to Zoetis stockholdersbbasic (in dollars per share)	$0.26	$0.32	$0.80	$0.89
Earnings per share attributable to Zoetis stockholdersbdiluted (in dollars per share)	$0.26	$0.32	$0.80	$0.89

Commitments_and_Contingencies_

Commitments and Contingencies (Details)	Sep. 29, 2013	Sep. 29, 2013	Sep. 29, 2013	Sep. 29, 2013	Aug. 13, 2013	Feb. 29, 2012	Sep. 29, 2013
In Millions, unless otherwise specified	USD ($)	EUR (€)	Roxarsone (3-Nitro) [Member]	PregSure [Member]	Ulianopolis, Brazil [Member]	Ulianopolis, Brazil [Member]	Mary Green [Member]
			plaintiffs	claims	plaintiffs	defendant	Roxarsone (3-Nitro) [Member]
			claims		defendant		claims
Loss Contingencies [Line Items]	'	'	'	'	'	'	'
Number of claims seeking damages	'	'	9	80	'	6	1
Number of plaintiffs	'	'	140	'	30	'	'
Number of claims settled	'	'	'	20	'	'	'
Number of additional defendants	'	'	'	'	57	5	'
Loss Contingency Accrual, Period Increase (Decrease)	$14	€ 11	'	'	'	'	'
Loss Contingency, Receivable, Current	$14	'	'	'	'	'	'

Segment_and_Other_Revenue_Info2

Segment and Other Revenue Information (Income Statement) (Details) (USD $)	3 Months Ended				9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013		Sep. 30, 2012		Sep. 29, 2013		Sep. 30, 2012		Dec. 31, 2012
					segment
Segment Reporting [Abstract]	'		'		'		'		'
Number of operating segments	'		'		4		'		'
Assets	$6,259	[1]	'		$6,259	[1]	'		$6,262	[1]
Segment Reporting Information [Line Items]	'		'		'		'		'
Revenue	1,103	[2]	1,019	[2]	3,307	[2]	3,160	[2]	'
Earnings	185	[3]	213	[3]	564	[3]	636	[3]	'
Depreciation and Amortization	49	[4]	54	[4]	151	[4]	156	[4]	'
Reportable Segment [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Revenue	1,103	[2]	1,019	[2]	3,307	[2]	3,160	[2]	'
Earnings	490	[3]	435	[3]	1,462	[3]	1,336	[3]	'
Depreciation and Amortization	25	[4]	31	[4]	74	[4]	77	[4]	'
Other business activities [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Earnings	-80	[3],[5]	-65	[3],[5]	-228	[3],[5]	-191	[3],[5]	'
Depreciation and Amortization	6		4	[4],[5]	19		12	[4],[5]	'
Corporate [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Earnings	-139	[3],[6]	-113	[3],[6]	-392	[3],[6]	-346	[3],[6]	'
Depreciation and Amortization	1	[4],[6]	1	[4],[6]	16	[4],[6]	18	[4],[6]	'
Purchase accounting adjustments [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Earnings	-12	[3],[7]	-13	[3],[7]	-37	[3],[7]	-39	[3],[7]	'
Depreciation and Amortization	12	[4],[7]	13	[4],[7]	37	[4],[7]	39	[4],[7]	'
Acquisition-related costs [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Earnings	-1	[3],[8]	-5	[3],[8]	-17	[3],[8]	-34	[3],[8]	'
Depreciation and Amortization	0	[4],[8]	5	[4],[8]	0	[4],[8]	10	[4],[8]	'
Certain Significant Items [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Earnings	-46	[3],[9]	-11	[3],[9]	-130	[3],[9]	-28	[3],[9]	'
Depreciation and Amortization	0	[4],[9]	0	[4],[9]	0	[4],[9]	0	[4],[9]	'
Other unallocated [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Earnings	-27	[10],[3]	-15	[10],[3]	-94	[10],[3]	-62	[10],[3]	'
Depreciation and Amortization	5	[10],[4]	0	[10],[4]	5	[10],[4]	0	[10],[4]	'
United States (U.S.) [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Revenue	495	[2]	448	[2]	1,386	[2]	1,294	[2]	'
Earnings	285	[3]	232	[3]	773	[3]	676	[3]	'
Depreciation and Amortization	11	[4]	11	[4]	33	[4]	26	[4]	'
Europe, Africa, and Middle East (EuAfME) [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Revenue	270	[2]	241	[2]	838	[2]	799	[2]	'
Earnings	92	[3]	91	[3]	300	[3]	283	[3]	'
Depreciation and Amortization	5	[4]	9	[4]	17	[4]	21	[4]	'
Canada and Latin America (CLAR) [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Revenue	171	[2]	165	[2]	555	[2]	549	[2]	'
Earnings	56	[3]	53	[3]	186	[3]	184	[3]	'
Depreciation and Amortization	5	[4]	5	[4]	14	[4]	17	[4]	'
Asia Pacific (APAC) [Member]	'		'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'		'
Revenue	167	[2]	165	[2]	528	[2]	518	[2]	'
Earnings	57	[3]	59	[3]	203	[3]	193	[3]	'
Depreciation and Amortization	$4	[4]	$6	[4]	$10	[4]	$13	[4]	'
[1]	The condensed consolidated balance sheet as of September 29, 2013 has been prepared under a different basis of presentation than the condensed combined balance sheet as of December 31, 2012, which significantly impacts comparability. See Note 3. Basis of Presentation.
[2]	Revenue denominated in euros were $159 million and $493 million in the three and nine months ended September 29, 2013, respectively and $142 million and $464 million in the three and nine months ended September 30, 2012, respectively.
[3]	Defined as income before provision for taxes on income.
[4]	Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
[5]	Other business activities reflect the research and development costs managed by our Research and Development organization.
[6]	Corporate includes, among other things, administration expenses, interest expense, certain compensation and other costs not charged to our operating segments.
[7]	Purchase accounting adjustments include certain charges related to the fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.
[8]	Acquisition-related costs can include costs associated with acquiring, integrating and restructuring acquired businesses, such as allocated transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring. For additional information, see Note 5. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.
[9]	Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, the impact of divestiture-related gains and losses and certain costs related to becoming a standalone public company. For additional information, see NoteB 5. Restructuring Charges and Other Costs Associated with Acquisition and Cost-Reduction/Productivity Initiatives. b"In the third quarter of 2013, certain significant items primarily includes: (i) Zoetis stand-up costs of $41 million; and (ii) litigation-related charges of $5 million. Stand-up costs include certain nonrecurring costs related to becoming a standalone public company, such as new branding (including changes to the manufacturing process for required new packaging), the creation of standalone systems and infrastructure, site separation, accelerated vesting and associated cash payment related to certain Pfizer equity awards, and certain legal registration and patent assignment costs.b"In the third quarter of 2012, certain significant items includes: (i) charges related to transitional manufacturing purchase agreements associated with divestitures of $1 million and (ii) $10 million for restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition.b"In the nine months ended September 29, 2013, certain significant items primarily includes: (i) Zoetis stand-up costs of $152 million; (ii) $26 million income related to a reversal of certain employee termination expenses; (iii) $6 million income on the government-mandated sale of certain product rights in Brazil that were acquired with the FDAH acquisition in 2009; (iv) additional depreciation associated with asset restructuring of $3 million; and (v) litigation-related charges of $5 million.b"In the nine months ended September 30, 2012, certain significant items includes: (i) $14 million income related to a favorable legal settlement for an intellectual property matter; (ii) $4 million income due to a change in estimate related to transitional manufacturing purchase agreements associated with divestitures; and (iii) $46 million for restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition.
[10]	Includes overhead expenses associated with our manufacturing operations

Segment_and_Other_Revenue_Info3

Segment and Other Revenue Information (Income Statement Narrative) (Details) (USD $)	3 Months Ended				9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013		Sep. 30, 2012		Sep. 29, 2013		Sep. 30, 2012
Segment Reporting Information [Line Items]	'		'		'		'
Revenues denominated in Euros	$159		$142		$493		$464
Restructuring charges	'		'		26		'
Legal Fees	'		'		'		2
Gain (loss) on disposition of assets	0	[1]	0	[1]	6	[1]	0	[1]
Other nonoperating income (expense)	-1		1		-2		1
Gain (loss) related to litigation settlement	'		'		'		14
Certain Significant Items [Member]	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Restructuring charges	'		'		26		'
Stand-up costs	41		'		152		'
Legal Fees	5		'		5		'
Gain (loss) on disposition of assets	'		'		6		'
Charges for manufacturing services agreements associated with divestitures change in estimate	'		1		'		4
Restructuring and implementation costs	'		10		'		46
Additional depreciation asset restructuring	'		'		3	[2]	'
Gain (loss) related to litigation settlement	'		'		'		$14
[1]	For the nine months ended SeptemberB 29, 2013, represents the net gain on the government-mandated sale of certain product rights in Brazil that were acquired with the FDAH acquisition in 2009.
[2]	Additional depreciation associated with asset restructuring represents the impact of changes in the estimated lives of assets involved in restructuring actions. For the nine months ended SeptemberB 29, 2013, included in Cost of sales ($1 million) and Selling, general and administrative expenses ($2 million). For the three months ended SeptemberB 30, 2012, included in Cost of sales ($4 million), Selling, general and administrative expenses ($1 million) and Research and development expenses ($1 million). For the nine months ended SeptemberB 30, 2012, included in Cost of sales ($9 million), Selling, general and administrative expenses ($1 million) and Research and development expenses ($10 million).

Segment_and_Other_Revenue_Info4

Segment and Other Revenue Information (Revenue by Animal Species) (Details) (USD $)	3 Months Ended				9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013		Sep. 30, 2012		Sep. 29, 2013		Sep. 30, 2012
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	$1,103	[1]	$1,019	[1]	$3,307	[1]	$3,160	[1]
Livestock [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	706		659		2,082		2,015
Cattle [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	388		365		1,134		1,136
Swine [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	155		140		465		425
Poultry [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	134		125		404		375
Other (Fish and Sheep) [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	29		29		79		79
Companion Animal [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	397		360		1,225		1,145
Horses [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	37		35		124		130
Dogs and Cats [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	$360		$325		$1,101		$1,015
[1]	Revenue denominated in euros were $159 million and $493 million in the three and nine months ended September 29, 2013, respectively and $142 million and $464 million in the three and nine months ended September 30, 2012, respectively.

Segment_and_Other_Revenue_Info5

Segment and Other Revenue Information (Revenue by Product) (Details) (USD $)	3 Months Ended				9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013		Sep. 30, 2012		Sep. 29, 2013		Sep. 30, 2012
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	$1,103	[1]	$1,019	[1]	$3,307	[1]	$3,160	[1]
Anti-infectives [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	333		299		920		882
Vaccines [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	298		266		877		812
Parasiticides [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	167		155		544		532
Medicated feed additives [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	93		105		294		298
Other pharmaceuticals [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	177		165		558		529
Other non-pharmaceuticals [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	$35		$29		$114		$107
[1]	Revenue denominated in euros were $159 million and $493 million in the three and nine months ended September 29, 2013, respectively and $142 million and $464 million in the three and nine months ended September 30, 2012, respectively.

Segment_and_Other_Revenue_Info6

Segment and Other Revenue Information Segment Assets (Details) (USD $)	Sep. 29, 2013		Dec. 31, 2012
In Millions, unless otherwise specified
Statement of Financial Position [Abstract]	'		'
Assets	$6,259	[1]	$6,262	[1]
[1]	The condensed consolidated balance sheet as of September 29, 2013 has been prepared under a different basis of presentation than the condensed combined balance sheet as of December 31, 2012, which significantly impacts comparability. See Note 3. Basis of Presentation.

Transactions_and_Agreements_wi2

Transactions and Agreements with Pfizer (Pre-Separation Period) (Details) (Pfizer [Member], USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2012	Sep. 30, 2012
Pfizer [Member]	'	'
Related Party Transaction [Line Items]	'	'
Costs of goods manufactured	$105	$320

Transactions_and_Agreements_wi3

Transactions and Agreements with Pfizer (Agreements with Pfizer) (Details)	Feb. 06, 2013
	manufacturing_site
Related Party Transaction [Line Items]	'
Number of manufacturing facilities	29
Pfizer [Member]	'
Related Party Transaction [Line Items]	'
Number of manufacturing facilities retained by Pfizer	14
Anchor Manufacturing Sites [Member]	'
Related Party Transaction [Line Items]	'
Number of manufacturing facilities	13
Satellite Manufacturing Sites [Member]	'
Related Party Transaction [Line Items]	'
Number of manufacturing facilities	16

Transactions_and_Agreements_wi4

Transactions and Agreements with Pfizer (Post-Separation Agreements with Pfizer) (Details) (Pfizer [Member], USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013
Transitional Services Agreement [Member]	'
Related Party Transaction [Line Items]	'
Amount charged under agreement with Pfizer	$63
Master Manufacturing and Supply Agreements [Member]	'
Related Party Transaction [Line Items]	'
Amount charged under agreement with Pfizer	130
Employee Matters Agreement [Member]	'
Related Party Transaction [Line Items]	'
Amount charged under agreement with Pfizer	99
Income Taxes Payable [Member]	'
Related Party Transaction [Line Items]	'
Due to related parties	$31